Hepatic stellate cells – from past till present: morphology, human markers, human cell lines, behavior in normal and liver pathology

RADA-TEODORA SUFLEȚEL1, CARMEN STANCA MELINCOVICI1, BOGDAN-ALEXANDRU GHEBAN2, ZAHARIE TOADER3, CARMEN MIHAELA MIHU1

1) Discipline of Histology, Department of Morphological Sciences, Iuliu Hațegianu University of Medicine and Pharmacy, Cluj-Napoca, Romania
2) Discipline of Pathological Anatomy, Department of Morphological Sciences, Iuliu Hațegianu University of Medicine and Pharmacy, Cluj-Napoca, Romania
3) Department of Pathology, Prof. Dr. Octavian Fodor Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania

Abstract
Hepatic stellate cell (HSC), initially analyzed by von Kupffer, in 1876, revealed to be an extraordinary mesenchymal cell, essential for both hepatocellular function and lesions, being the hallmark of hepatic fibrogenesis and carcinogenesis. Apart from their implications in hepatic injury, HSCs play a vital role in liver development and regeneration, xenobiotic response, intermediate metabolism, and regulation of immune response. In this review, we discuss the current state of knowledge regarding HSCs morphology, human HSCs markers and human HSC cell lines. We also summarize the latest findings concerning their roles in normal and liver pathology, focusing on their impact in fibrogenesis, chronic viral hepatitis and liver tumors.

Keywords: hepatic stellate cells, vitamin A, fibrosis, chronic viral hepatitis, liver tumors.

Introduction
Hepatic stellate cell (HSC), also known as Ito cell, fat storing cell, lipocyte, perisinusoidal cell or parasinusoidal cell [1–3] was first studied by von Kupffer, who used a special staining, gold chloride technique, which detected lipid droplets of vitamin A in the stellate cell cytoplasm [2, 4]. He called them “sternzellen” (star-shaped cells) [2, 4, 5], their uniqueness being validated by Rothe, in 1882 [2, 5]. HSCs have been highlighted by various stainings, including a lipid staining used by Ito to define the “fat storing cell” [2, 6], and silver impregnation used by Suzuki to analyze “interstitial cells”. Bronfenmajer et al. [2, 7] came with the name “lipocytes” to demonstrate their essential function in fat storage (vitamin A). Researchers like Ito, Nakane & Wake revealed that stellate cells are capable to deposit lipids and vitamin A [2]. Kent et al. had discovered an essential function of stellate cells in liver cell repair, highlighting the proximity of these cells to collagen fibers in the injured liver [2, 8]. The international community of investigators proposed the name of “hepatic stellate cells” to these cells, in 1996 [9]. The association between the morphological features of HSCs and the extracellular matrix (ECM) [2, 10] caused a huge interest in the early 1980s, leading to the development of stellate cell isolation methods in rats [2, 11], mice [2, 12] and human liver [2, 13, 14].

Due to their key functions in liver homeostasis and fibrogenesis, enormous progress has been made in their study using cellular isolation methods, genetic analysis methods, flow cytometry, real-time quantitative polymerase chain reaction (PCR), confocal imaging, immunohistochemical (IHC) markers revealing their cellular origin and phenotype [2] and Raman spectroscopy [15, 16]. Improved knowledge of these cells and their crucial roles will open new therapeutic perspectives in patients with liver diseases.

Ultrastructural and morphological aspects of HSCs
HSCs represent structural and non-parenchymal cells (NPCs), fat-storing pericytes [17] existing in the subendothelial space of Disse, between the basolateral surface of hepatocytes and the antiluminal side of sinusoidal endothelial cells (SECs) [18, 19]. In healthy liver, they account approximately 1.5% of the whole hepatic parenchyma and 1/3 of the NPCs, representing 10–15% of all hepatic resident cells [19, 20].

The embryological origin of Ito cells was a controversial debate topic. Nowadays, most studies suggest both the endodermal (cytokeratins) [2, 21, 22] and septum transversum mesenchyme [forkhead box fl (Foxf1), vimentin] origin [2, 23, 24]. The theory related to the neuroectodermal origin of stellate cells due to their expression of glial markers [glial fibrillary acidic protein (GFAP), synaptophysin (SYN), neural cell adhesion molecule (N-CAM) and p75] [2, 19, 25–27] has been denied [2, 24].

This is an open-access article distributed under the terms of a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License, which permits unrestricted use, adaptation, distribution and reproduction in any medium, non-commercially, provided the new creations are licensed under identical terms as the original work and the original work is properly cited.
HSCs (from the Latin terminology “stella”, meaning star) exhibit a star-like shape [25, 28] and their dendritic cytoplasmic processes surround the neighboring endothelial cells [20, 28], just like astrocytes and podocytes embrace the terminal cerebral blood vessels, respectively, the glomerular capillaries. By electron microscopy, the cellular body of stellate cell is reduced in volume, spindle shaped and contains a voluminous nucleus, oval or elongated, often compressed by lipid vacuoles of vitamin A [2]. These vacuoles usually represent 20% of the cell volume, but their distribution from one cell to another is very different [2]. In non-fixed tissues or in cell cultures, under the action of 328 nm light, the lipid vacuoles of vitamin A express a blue green autofluorescence that diminishes rapidly [2, 29, 30]. The amount of lipid vacuoles varies directly in proportion to the species and the amount of retinol reserves in the body [2, 31, 32]. In the stellate cell, the vacuoles of vitamin A have a mixed appearance, meaning that the variation in the number of vacuoles depends on the localization of the cells within the hepatic lobule [2, 25, 31]. The fluorescence of retinol is more pronounced around the portal and central zones [2, 31, 33, 34]. Two types of vitamin A vacuoles have been described [2, 19, 30, 35]. Type I vacuoles are membrane-bound vacuoles with variable sizes, that measured less than 2 μm in diameter and derive from “multivesicular corpuscles”, a form of lysosomes [2, 19, 30, 36, 37]. The second type vacuoles are not linked to the membrane and are larger in size, over 8 μm. The relationship between types I and II vacuoles and their functional differences is unclear [2, 19, 30]. According to Wake’s study, type II lipid vacuoles resulted from the fusion of several type I vacuoles [35]. Furthermore, Yamamoto & Ogawa [36] considered that type II lipid vacuoles resulted from type I vacuoles, emerging into the spaces in between hepatocytes and attaining the cytoplasmic processes of other stellate cells [25, 28]. Cellular organelles of HSCs are those of a secretory cell, with a moderately developed rough endoplasmic reticulum, a reduced juxtanuclear Golgi apparatus and protruding dendritic cytoplasmic processes [2, 25]. Ito cells send different types of visible cytoplasmic extensions, some of which are inter-hepatic, and others are subendothelial prolongations [2, 25, 38]. These subendothelial prolongations display microprojections, like thorns, by which the Ito cell establishes contacts with the hepatocytes [2, 38, 39]. These microprojections detect the chemotactic stimuli and transmit them to the mechanical apparatus of the cell to generate contraction [2, 38, 40]. Due to the close contacts between stellate cells, hepatocytes, Kupffer cells and sinusoids, the transport of soluble mediators and cytokines is simplified [2, 38]. In addition, stellate cells are adjacent to autonomic nerve endings [2, 38, 40, 41], which is why they respond to α-adrenergic stimulation.

In hepatic cell injury, the morphological features of HSCs undergo important transformations [2, 28]. They lose their characteristic lipid vacuoles and become activated [19, 28, 38, 42, 43], modifying their appearance and adopting a huge flat shape. Their rough endoplasmic reticulum increases, due to the activation of protein synthesis [2, 28, 38, 44] and in the cytoplasm appear many contractile microfilaments [2, 25, 28, 38]. Ito cells undergo transformation into myofibroblast (MFB)-like cells, capable of contraction, proliferation and fibrogenesis [2, 19, 28, 38, 42]. Thus, according to the various physiological conditions, there are two types of stellate cells: quiescent and activated [2, 19, 28, 38].

It seems like the number, morphology, and cytokine status of quiescent and activated HSCs in the liver are changed in diverse stages and circumstances of liver injury [2, 19, 28].

### Human HSCs markers

Over the past few years, with the discovery of a wide range of specific markers for Ito cells, these cells were extremely well characterized [2]. Thus, stellate cells can be detected using different markers, like those with ectoderm origin [e.g., GFAP, nestin, neurotrophins and their receptors, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), SYN and N-CAM]; mesoderm origin [vimentin, desmin, alpha-smooth muscle actin (α-SMA) and hematopoietic markers] and lecithin retinol acyltransferase (LRAT) [19, 45].

In 1984, Yokoi et al. found that stellate cells of rodents expressed desmin [2, 46, 47]. Desmin, a muscle-specific type III intermediate filament [19], represents a ‘gold standard’ for detecting HSCs in rodent liver, but its utility has been shown to be reduced due to its low expression in human Ito cells [2, 46, 47]. The positivity of desmin in HSCs has been controversial [46, 48–50]. Some studies indicate that HSCs lack desmin expression in normal and fibrotic human livers [2, 46, 48, 51, 52]. Other studies show that Ito cells express positive desmin immunoreactivity in normal [46, 50] and cirrhotic human liver [46, 49]. While researches revealed the existence of desmin-positive stellate cells near blood vessels in fetal liver [19, 53], transformation of HSCs into MFB has also been shown to be related with amplified desmin production and development of desmin containing intermediate filaments in a vimentin-dependent way [19, 53].

α-SMA, an actin isoform, represents the only most consistent marker of activated and myofibroblastic HSCs [2, 19, 28, 46, 54] because it is not present in other liver cells, except portal MFBs and vascular smooth muscle cells [46, 49, 55]. Ito cells show a strong positivity for α-SMA in chronic liver disease (Figures 1 and 2) [46, 49, 56, 57]. Some reports have shown no α-SMA immunoreactivity in healthy human liver [46, 55, 58]. Yet, it was proven that α-SMA can also be expressed by quiescent HSCs in normal liver by applying very sensitive detection methods [19, 59].

In addition, HSCs express vimentin, vinculin, procollagens I, III, collagen IV, V, laminin, and fibronectin [13, 46, 60–62]. HSCs also possess neurotrophin receptors (neural markers) like GFAP, p75 nerve growth factor receptor (p75NGFR), tyrosine kinase receptor 3 (Trk-C), N-CAM, neurotrophin-3 (NT-3) and SYN [46, 63].

GFAP is an intermediate filament, expressed by astrocytes, providing support and strength for these cells [64, 65]. It seems that HSCs also express GFAP, which is involved in the restoration of the vasculature of injured hepatic tissues during liver fibrosis [19, 66]. Some studies revealed GFAP immunoreactivity in Ito cells during...
Hepatic stellate cells – from past till present: morphology, human markers, human cell lines, behavior in normal...  

Different stages of chronic hepatitis [46, 51]. Also, some authors described a small population of HSCs that were GFAP positive in normal human liver [46, 67]. There are studies suggesting that GFAP is a more specific marker than α-SMA in detecting early active HSCs [65, 66]. Thus, GFAP has a double utility [19], being a marker for quiescent HSCs [68] or an early marker of HSCs activation [66].

Figure 1 – Activated stellate cells show strong α-SMA cytoplasmic immunostaining in a liver biopsy of a hepatitis B-positive patient. CytoViva’s Hyperspectral Microscope, image with the patented CytoViva darkfield-based microscope, smoothing and subsetting mood. Anti-α-SMA antibody immunostaining, ×200. The image was captured at the Research Center for Advanced Medicine, MedFUTURE, Iuliu Hățieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, during my PhD training. α-SMA: Alpha-smooth muscle actin.

Figure 2 – Activated stellate cells show strong α-SMA cytoplasmic immunostaining in a liver biopsy of a hepatitis C-positive patient. CytoViva’s Hyperspectral Microscope, image with the patented CytoViva darkfield-based microscope, filter square root. Anti-α-SMA antibody immunostaining, ×200. The image was captured at the Research Center for Advanced Medicine, MedFUTURE, Iuliu Hățieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, during my PhD training. α-SMA: Alpha-smooth muscle actin.

p75NGFR had shown a low expression in HSCs of healthy human livers [46]. Also, HSCs of cirrhotic livers were strongly positive for p75 [46, 51, 63, 69], while inactive HSCs were negative for p75 [46, 69].

Trk-C was positive in Ito cells of normal and injured human liver [46, 51, 63]. Some studies reported that cultured HSCs lost their Trk-C expression [46, 70].

N-CAM was positive in perportal and intermediate-zone HSCs of normal human liver [46]. Also, Ito cells of cirrhotic human liver were immunoreactive for N-CAM [46, 51].

NT-3 was expressed in Ito cells of normal and cirrhotic alcoholic liver [46, 51]. Also, a low immunoreactivity of NT-3 was found in hepatocytes of normal human liver [46, 63].

SYN represents a plasma membrane glycoprotein with affinity for neural tissues and is involved in the liberation and/or uptake of neurotransmitters in the synapse [19, 71]. It was strongly expressed by perisinusoidal HSCs in healthy liver, and also had shown enhanced immunoreactivity in chronic biliary disease and chronic viral hepatitis C [46, 51, 72, 73].

Ito cells express retinol processing proteins [cellular retinol-binding protein-1 (CRBP-1), cytoglobin/stellate cell activation-associated protein (CYGB/STAP) and LRAT] and other membrane proteins [fibroblast activation protein (FAP) and platelet-derived growth factor receptor beta (PDGFRβ)] [3, 46].

CRBP-1 is responsible for the intracellular transport of retinol [46]. Lobular stellate cells were positive for CRBP-1 and the immunoreactivity did not respond to smooth muscle cells and cholangiocytes positivity [46, 61]. The expression of CRBP-1 was low in human livers with intense fibrosis, probably because of the loss of vitamin A [46, 62].

CYGB/STAP represents a component of the globin family, revealed in 2001 as a protein related with HSCs activation [74, 75]. It was shown that CYGB could modulate oxygen homeostasis [75]. It seems that when the oxygen homeostasis is disturbed, HSCs are activated and have main functions in liver fibrogenesis [75]. CYGB has a strong immunoreactivity in quiescent Ito cells of human livers [46]. Studies have shown that in fibrotic and cirrhotic human livers the distribution of CYGB was exclusive with the distribution of Thy-1 and fibulin-2 (FBLN2) [46, 62]. It has been revealed that cytoglobin immunoreactivity is associated with a more quiescent phenotype of HSCs and is modulated by ECM proteins via focal adhesion kinase (FAK) signaling in rat HSC-T6 cell line [46, 76].

LRAT proved to be a quiescent HSC marker in human hepatic tissue [46, 58]. LRAT is an enzyme with a vital role in vitamin A metabolism within the liver [30, 46, 77] and a specific marker for HSCs [46, 78]. A study reported that HSCs which express both LRAT and CRB-1 are partially responsible for portal fibrogenesis in human viral hepatitis [46, 79].

FAP is a cell surface-bound protease of the prolyl oligopeptidase gene family expressed at sites of tissue remodeling [46]. Ito cells of cirrhotic human liver were immunoreactive for FAP [46]. In normal human livers, Ito cells did not express FAP [46]. It was reported an association between the positivity of FAP and the severity of liver fibrosis [46, 80].

PDGFRβ was the first membrane receptor discovered...
on PDGFRβ and PDGFRα [46, 50, 81–84] and several studies revealed an increased immunoreactivity of PDGFRβ in Ito cells of cirrhotic human liver [46, 85].

Other markers expressed by HSCs are programmed death-ligand 1 (PD-L1) and alpha B-crystallin (ABCRYS) [46]. PD-L1 also known as B7-H1 is a co-stimulatory molecule positive only in activated HSCs [46, 86]. ABCRYS was expressed by perisinusoidally stellate cells in healthy and cirrhotic human livers [46, 51, 70, 87].

### Human HSCs lines

In order to accomplish the primary cell isolation, stellate cell clones, which share several characteristics of activated HSCs, have been created [2]. The immortalized HSCs clones have been used in a broad range of studies and have shown to be an important key in understanding HSCs biology and liver fibrosis [46]. It seems that these immortalized cell lines are perfect for genetic research due to their wide resource supply and homogeneity [2, 46].

The current HSCs lines have been produced from primary HSCs by using spontaneous immortalization during long-term culture or by transformation with the simian virus 40 large T-antigen (SV40LT) or ectopic expression of human telomerase reverse transcriptase (hTERT) [2, 46]. All the reported cell lines proved to be nontumorigenic [46].

A wide range of cell lines have been described, below we discuss the most extensively studied human HSCs lines [2].

The first human HSC line described in the literature was the L190 cell line isolated from a human epithelioid hemangioendothelioma [2, 46, 88]. These cells share similar features with HSCs [2, 46]. They contain lipid droplets rich in vitamin A, express α-SMA, vimentin, matrix elements like collagen I, III, IV, V and VI, fibronectin, laminin and matrix metalloproteinases (MMPs) [2, 3, 89]. They are negative for desmin and endothelial or monocyte/macrophage-lineage markers [46].

Other cell lines are TWNT-1 and TWNT-4, generated from L190 line by retrovirally induced human telomerase reverse transcriptase [2, 46]. TWNT-1 express HGF, vascular endothelial growth factor receptor-1 (VEGFR-1), Collα1, Collα2, α-SMA, PDGFRβ, vimentin and transforming growth factor-beta 1 (TGF-β1) [46].

### The roles of HSCs in healthy liver

#### Metabolism of vitamin A

Vitamin A and its metabolites are indispensable in maintaining the systemic homeostasis, including normal cell division and differentiation, immunoregulation, normal reproduction and vision [30, 43, 99]. Retinyl ester, retinol, retinal and retinoic acid (RA) represent the main retinoid components of the body [100, 101].

Under normal conditions, most of body’s vitamin A (80–90%), is deposited in the liver, as lipid droplets, within the cytoplasm of HSCs [2, 30, 38, 43, 99]. Thus, HSCs have a major role in storing and transporting vitamin A and its metabolites.

Dietary vitamin A is absorbed in the intestinal epithelium and delivered to the liver, incorporated in chylomicrons. In the liver, the chylomicrons cross sinusoidal capillaries and reach hepatocytes [2, 30, 38, 43, 99]. Within hepatocytes, retinol esters are converted to free retinol and then quickly transferred to HSCs or storage. A small part is left within hepatocytes [2, 30, 38, 43, 99].

Biochemically, the major components of HSCs lipid droplets are retinyl esters (the most abundant is retinyl palmitate), triglycerides, cholesterol, cholesteryl ester, phospholipids, and free fatty acids [2, 30, 38, 43, 102]. It is demonstrated that the composition, number, and size of lipid droplets are highly influenced by retinoids acquired from diet and not by dietary triglyceride intake [2, 30, 43]. In conditions of intensive dietary retinoid intake, the number and size of the lipid droplets increase, to regulate the retinoid. In conditions of low dietary retinoid intake, the number and size of lipid droplets decrease, in order to ensure tissue retinoid needs [2, 30]. Also, several studies reported important differences between the species, regarding the number of Ito cells localized in the liver and the number and size of lipid droplets contained in their cytoplasm [2, 31, 103, 104].
findings, HSCs lipid droplets are considered specialized organelles involved in the storage of retinoids [30, 104].

Many proteins involved in the metabolism of HSCs lipid droplets have been discovered, including adipocyte differentiation-related protein (ADRP), perilipin-3 (TIP47), CRBP, retinol palmitate hydrolase, cellular retinoic acid-binding protein (CRABP), bile salt-dependent and -independent retinol ester hydrolase, diacylglycerol acyltransferase 1 (DGAT1), and LRAT [2, 105].

A study conducted by Straub et al. revealed that ADRP and TIP47 are localized in HSCs lipid droplets of healthy mouse, bovine, and human liver [106]. ADRP and TIP47, components of PAT protein family, have a key role in the stabilization of lipid droplets in HSCs, just like in other cells [30].

Due to their role in storing retinoids, HSCs have high concentration of CRBP1 and LRAT. LRAT, an enzyme present in rough endoplasmic reticulum and the “multivesicular bodies” of HSCs has a crucial role in the genesis of HSCs lipid droplets, being involved in all retinol formation within the liver [30, 58]. HSCs also contain high levels of DGAT1 [30, 107], an enzyme responsible for triglyceride formation that is used for integration within HSCs lipid droplets [30, 107]. It was reported that DGAT1 can mediate the synthesis of retinyl ester from retinol and fatty acyl-CoA [30, 100, 108, 109].

Retinoids play a key role in modulating HSCs activation [30, 43, 110, 111]. After hepatic insult, Ito cells immediately lose their lipid droplets and retinoid deposits. Also, the expression of LRAT and peroxisome proliferator-activated receptor gamma (PPARγ) decrease [30, 43, 110, 111]. It seems that loss of HSCs lipid droplets is the trigger in the development of hepatic disease [30]. Leo & Lieber observed that hepatic retinoid stores were lower during the progression of alcoholic liver disease (ALD) [30, 112]. They suggested that low levels of hepatic retinoids were either caused by high degradation of the liver retinoid content or by increased mobilization of the retinoid to peripheral tissues [30, 112]. Regarding the existing reports, most retinoids are catabolized [43]. Retinol dehydrogenase 13 (RDH13), alcohol dehydrogenase 3 (ADH3) and adipose triglyceride lipase (ATGL) mediate the retinoid catabolism [43, 113–115]. It was shown that mice with low levels of RDH13 and ADH3 had a mild liver damage and fibrosis, after carbon tetrachloride (CCL4) exposure, revealing their main role in fibrogenesis [43, 113, 114]. Also, it seems that ADH3 stimulates HSCs survival by suppressing natural killer (NK) activity [43, 114].

The contribution of retinol metabolism in HSCs activation is also highlighted by two metabolites of the RA catabolism, 9-cis-RA and 9,13-di-cis-RA, which stimulate fibrogenesis by promoting the synthesis and activation of TGF-β1 [2, 43, 116]. The studies regarding the roles of retinoids on HSCs and development of fibrosis are not fully understood [43]. It was reported that retinol and RA inhibited HSCs activation in culture [2]. Some studies have shown that RA treatment reduces fibrosis while others have proven that RA stimulates fibrogenesis [43, 117]. It seems like retinoids can change activated HSCs back into the quiescent form [43, 118]. This feature could influence treatment in different liver pathologies.

Regarding the retinol mobilization, the main enzyme involved in this process is patatine-like phospholipase domain containing protein 3 (PNPLA3), which has triglyceride hydrolase, acetyl-CoA independent transacylase and retinyl esterase properties [43, 119]. The PNPLA3 H148M mutation is responsible for the loss of enzymatic activity and future changes in triglyceride metabolism, which leads to alcohol liver disease, non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC) [43, 120]. The contribution of this mutation in retinol metabolism is less known [43]. This mutation could be responsible for HSCs activation, regarding the fact that expression of mutant PNPLA3 in HSCs leads to retinol loss; even so, increased lipid droplet levels were associated with high release of proinflammatory cytokines [43, 121].

Testerink et al. studied in vitro the catabolism of lipid droplets in rat HSCs using confocal Raman micro-spectroscopy and mass spectrometric analysis of lipids (lipidomic) [16]. They noticed that during activation, HSCs lipid droplets became smaller, but more numerous during the first seven days and the overall volume of neutral lipids was not reduced. It was shown that after seven days, HSCs had lost the majority of their retinyl esters, but preserved their triacylglycerols and cholesterol esters. Also, the investigators observed increased levels of polyunsaturated fatty acids in HSCs lipid droplets, which replaced the retinyl esters. This process supports the idea that both types of lipids influence the activation of HSCs [16]. A study conducted by Galler et al. evaluated the retinoid content of HSCs obtained from healthy mice livers and mice livers treated with lipopolysaccharide (LPS), which induces an inflammatory state, using Raman spectroscopy, in order to reflect the role of retinoid content in hepatic health [15]. They observed that retinoid state was lower in liver samples from LPS-treated mice than in liver samples from healthy mice. Thus, the HSCs retinoid content could be used as a clinical marker to assess the hepatic health state [15].

The impact of HSCs in hepatic development and regeneration

HSCs have a central role in liver regeneration, being components of the hepatic progenitor cell niche [2, 122]. This statement is suggested by the observation that mouse fetal liver mesenchymal cells, which have similar aspects of HSCs (α-SMA, desmin, and vimentin), stimulate the maturation of hepatoblasts by cell–cell contact in cell culture [2, 123]. It seems like several growth factors and mitogens are synthesized by HSCs including Wnt9a protein [124], HGF [125], pleiotrophin [126], epidermal growth factor (EGF) [2, 127] and fibroblast growth factor 10 (FGF10) [128, 129]. All of them have a great contribution in the hepatocyte’s proliferation through organ development and regeneration [130].

HSCs are implicated in hepatoblast differentiation by establishing cell–cell contact with hepatic epithelial cells and by secreting ECM components which influence hepatocyte and biliary cells fate [130]. Furthermore, Ito cells have a major role in the formation of intrahepatic bile ducts during development [130, 131], idea supported by the fact that rat HSCs express Notch receptors and target genes of Notch signaling [130, 132], which are...
vital in the differentiation and morphogenesis of intrahepatic biliary epithelial cells [133]. In addition, there are reports about paracrine interactions between bile duct epithelium and either HSCs or portal fibroblasts both in culture [2, 134] and in vivo [2, 135]. Another finding that highlights the involvement of HSCs in the development of intrahepatic bile ducts is represented by the expression of synemin (an intermediate filament characteristic for HSCs) in both stellate cells and bile ductular epithelial cells, in response to different liver pathologies and cholangiocarcinoma [2, 136].

HSCs may influence the growth, differentiation, or morphogenesis of all the hepatic parenchymal cells, observation supported by the close contacts during development between HSCs, endothelial cells, hematopoietic and hepatic epithelial cells [38, 130].

During angiogenesis, tight contacts between pericytes and endothelial cells represent an important process in the consolidation of vascular elements [130, 137]. HSCs are considered to be the pericytes of the liver and have a major involvement in the development of the hepatic vasculature [130, 138]. This idea is supported by the observation that in mice, lack of β-catenin in the liver mesenchyme leads to HSCs activation and the liver is occupied by dilated sinusoids [130, 139].

There are reports that highlight the role of HSCs in fetal liver hematopoiesis [130]. Their involvement in liver hematopoiesis is demonstrated by the fact that in mice without the HSCs–expressing $H_{\alpha}$ homeobox gene, fetal liver hematopoiesis is markedly affected [130, 140]. In addition, fetal HSCs express stromal cell-derived factor 1α (SDF1α; also known as CXCL12) [141], a strong chemoattractant for hematopoietic stem cells [130]. Thus, they are responsible for the recruitment of hematopoietic stem/progenitor cells into the fetal liver [130].

Another interesting finding is that HSCs could have a pluripotent role in developing or adult liver due the fact that some of them express cluster of differentiation 133 (CD133), which is a stem cell marker [2, 142]. Furthermore, it was discovered that CD133 is marker of stem-like cells in several tissues [143, 144], including colon cancer [145, 146].

In addition to their key role in hepatic development, there are numerous reports that HSCs represent the hallmarks of the hepatic regenerative process in adult liver [130]. Knowing the mechanisms of liver regeneration is vital for developing new strategies of differentiating and propagating hepatocytes in vitro, also for promoting hepatic recovery and increasing survival after acute liver failure, liver transplantation, or resection [130]. The most familiar and usual method to explore liver regeneration is partial hepatectomy (PH) [130, 147–149]. After this procedure, liver regeneration is obtained by the proliferation of residual hepatocytes and takes place in the absence of inflammation or necrosis [2, 148]. If the proliferation of hepatocytes collapse, it looks like liver regeneration is generated by the activation of other types of cells like oval cells or liver progenitor cells [2, 148].

Activated HSCs are involved in liver regeneration by secreting angiogenic factors, also cytokines, that mediate endothelial cell and hepatocyte proliferation and by remodeling ECM elements [2, 130, 150]. At initial stages of liver regeneration, Ito cells stimulate the proliferation of liver progenitor cells and hepatocytes [130]. Latest reports reveal the possibility that HSCs could pass through a mesenchymal-to-epithelial transition to become liver progenitor cells and give rise to hepatocytes [130, 151].

The contribution of HSCs in hepatic regeneration is supported by the observation that suppressing activated HSCs using glitoxin [152, 153] and L-cysteine [154] stops normal regenerative responses of both hepatocytes and oval cells in Acetaminophen and 2-Acetylamino-fluorene (2-AAF)/PH-induced liver injuries [130]. Also, Foxf1+/− (forkhead transcription factor) mice treated with CC1 reveal low HSCs activation and increase hepatocyte necrosis during the regenerative period [23, 130]. It seems that activated HSCs secrete a wide range of cytokines and chemokines [2, 130], which could directly influence the proliferation of liver progenitor cells and hepatocytes or could indirectly stimulate liver regeneration by SECs and immune cells [130]. It was demonstrated that HSCs isolated from rats during initial liver regeneration after 2-AAF/PH injury produce high levels of HGF and stimulate oval cell proliferation [130, 155]. p75 neurotrophin receptor (p75NTR), which is expressed in human HSCs after fibrotic liver insult, could modulate the synthesis of HGF by HSCs [130, 156].

It was noticed that in mice, loss of p75NTR suppressed hepatocyte proliferation in vivo, p75NTR−/− HSCs could not differentiate to MFBs and did not promote hepatocyte proliferation. In addition, suppression of p75NTR signaling to the small guanosine triphosphatase Rho affects HSCs differentiation [130, 156]. Another key factor that modulates the contacts between HSCs and hepatocytes during regeneration is hedgehog (Hh) signaling [130, 157]. It was observed that in vivo, hepatocyte proliferation is initiated by Hh ligand following PH [130, 158]. In culture, activated HSCs produce Sonic hedgehog (Shh), which has an autocrine growth factor role for these cells [130, 157].

Activated HSCs have a primordial role in ECM remodeling, being the central source of MMPs and their inhibitors, associated with ECM remodeling [130]. It seems like the synthesis of cytokines and remodeling of the ECM are linked, due the fact that the ECM has the ability of sequestering biologically active molecules [159, 160]. Besides cytokine secretion, stellate cells can regulate their role by splitting or releasing cytokines from the ECM [130].

The liver regeneration process has numerous phases that implicate induction and finalization of hepatic development. This process finishes when the liver accomplishes a propiate cellular mass [130, 161]. HSCs secrete the best-known hepatocyte antiproliferative factor TGF-β1 [162]. In the final steps of liver regeneration, HSCs suppress hepatocyte proliferation and even initiate apoptosis by secreting increased quantities of TGF-β1 [130, 149]. It was demonstrated that in culture, serotonin enhances the expression of TGF-β1 in mice HSCs, due the 5-hydroxytryptamine 2B (5-HT2B) receptor, and 5-HT2B inhibition stimulates hepatocyte proliferation after PH, bile duct ligation (BDL) and CC1-induced liver insult [163]. HSCs could modulate the induction and finalization of liver...
regeneration by modifying their cytokine expression profile during this process [130].

In order to get an overview of the role of HSCs in hepatic regeneration, their particular ablation during various phases in the regenerative process is required [130]. At this moment, this process is not feasible.

Genetic methods have discovered new regeneration models like the nitroreticulate/Metronidazole cell ablation system [164] and morpholino-based knockdown of a mitochondrial import gene to initiate hepatocyte death [165]. One future method is to create high-throughput chemical screens in different zebrafish models of liver insult, searching drugs that influence HSCs during hepatic regeneration [166].

The contribution of HSCs in liver immune system

HSCs represent the hallmarks of hepatic immunoregulation [2, 17, 167]. This statement is supported by HSCs relationship with inflammatory cells, regulating their activity or stimulating their differentiation [2, 167]. Moreover, HSCs can behave like antigen-presenting cells (APCs), have autophagy ability, secrete many immune factors like cytokines [e.g., interleukin-17 (IL-17)] and chemokines [chemokine (C–C motif) ligand 2 (CCL2)], react to numerous immunological stimuli by expressing Toll-like receptors (TLRs) (e.g., TLR4, TLR9) and transduce signals through pathways and mediators located in immune cells, like Hh pathway or inflammasome activation [17]. In normal conditions, HSCs support immunosuppressive responses, e.g., initiation of regulatory T-cells (Tregs), T-cell apoptosis (via PD-L1) or inhibition of cytotoxic CD8 T-cells. In case of hepatic insult, HSCs detect the affected tissue and promote the activation of innate immune cells [17].

It seems like the interactions between HSCs and liver immune cells are bidirectional [19]. HSCs receive many stimuli from leukocytes, intensify these signals and in response elaborate immune mediators that regulate leukocytes behavior [17, 19]. The main HSCs activation pathway is represented by the nuclear factor-kappa B (NF-κB) that stimulates LPS or TLR4 or adenosine triphosphate (ATP)-induced cytosolic Ca²⁺ influx through purinergic signaling receptors like P2Y [17, 168].

HSCs support leukocyte recruitment and adhesion, and in addition regulate their activation within the hepatic environment by producing immunomodulatory cytokines [19, 167]. Ito cells can increase the immune response by initiating infiltration of mono- and polymorphonuclear leukocytes [2]. HSCs modulate the recruitment of inflammatory cells, such as neutrophils, macrophages/monocytes, NK/NKT cells, by elaborating a wide range of chemokines like CCL2 [169], CCL5 [170], CCL21 [171], CCL4 [172], C-X3-C motif chemokine ligand 1 (CX3CL1) [172–174], and others. Furthermore, most of these chemokines have the property to directly regulate the activation, differentiation, proliferation, survival, and apoptosis of leukocytes [19].

HSCs activity is influenced by particular lymphocyte populations [2]. Thus, CD8 cells have an intense fibrogenic activity via stellate cells in comparison with CD4 cells [175], observation which was supported by the fact that high amount of liver fibrosis was noticed in patients with both hepatitis C virus (HCV) and human immunodeficiency virus (HIV) where CD4+/CD8+ cells rate was lower than in patients with only HCV infection [2].

There are evidences that in vitro, activated HSCs have a marked T-cell inhibitory capacity due to increased expression of PD-L1 (also known as B7-H1 or CD274), that has a key function in suppressing adaptive immune responses [17, 86]. The expression of PD-L1 is activated by interferon-gamma (IFN-γ) and contrary PD-L1 inhibition leads to the decrease of HSCs immunoregulatory activity, both in humans and mice. Quiescent HSCs do not express PD-L1 [17].

Stellate cells may act as professional APCs [176–178] that can promote lymphocyte proliferation or apoptosis [2, 179]. This property is supported by the fact that they express components of the major histocompatibility complex (MHC class I and MHC class II), lipid presenting molecules (CD1b and CD1c), and costimulatory molecules that contribute to T-cell activation (including CD40, CD80 and CD86) [19]. Activated HSCs have the capacity to internalize macromolecules and regulate T-cell proliferation [19, 177]. During human fibrosis, Ito cells can play as APCs, on account of the fact that they intensively express human leukocyte antigen class II (HLA-II) and CD40 in human cirrhotic livers [19].

Several reports have demonstrated that Ito cells are involved in the activation of T-cell responses by showing lipid and protein specific antigens to CD1d, MHC-I-, and MHC-II-restricted T-cells [178]. Recently, it was proven that highly purified HSCs upregulate MHC class II only in conditions of IFN-γ stimulation, supporting the fact that at steady state, HSCs may not have the antigen presentation and costimulatory properties [180]. It was established that, in order to act like APCs, stellate cells need RA, dendritic cells (DCs) and TGF-β1, which promote T-lymphocytes activation and could initiate differentiation of forkhead box p3 (Foxp3)+ subpopulation [181].

This theory supports the immunomodulation role of HSCs. Increase expression of CD54 in HSCs stops the activation of naïve T-cells by DCs by limiting IL-2 and interleukin-2 receptor (IL-2R) expression on T-cells [182]. This ability of Ito cells to modulate T-cell response could be used as an alternative mechanism to regulate T-cell suppression and tolerance in the liver [182]. All these findings show that HSCs have a primordial role in liver immunity.

The role of HSCs in xenobiotic metabolism, pH regulation and oxidant stress response

It was reported that HSCs contain enzymes like alcohol dehydrogenase [183] and acetaldehyde dehydrogenase [184] that contributes both in intermediary metabolism and detoxification of ethanol and xenobiotics [2].

Ito cells express different isoforms of cytochrome P450 [2, 19] like CYP2C11, CYP3A2, CYP2D1, CYP2S1 [185], and CYP3A [186]. It seems that during cellular activation, the activity of these enzymes is reduced [2, 187]. This finding could be essential in xenobiotic detoxification and oxidant stress response [2]. The α-, μ-, and π-isofoms of glutathione S-transferase (GST) enzymes, found in HSCs using enzymatic assay and
Northern and Western blots [188], are fundamental for detoxification of xenobiotics and the response to oxidant stress, due to their roles in both normal liver function and response to injury [189]. In addition, stellate cells express CYGB, an endogenous peroxidase that catalyzes hydrogen peroxide and lipid hydroperoxides [74].

In vivo [2], HSCs activation initiates the accumulation of glutathione synthase [190] and mRNA for the glutathione peroxidase I, the selenium-dependent isoformal [191], in stellate cells. It seems like glutathione levels could make the difference between oxidative stress and activation due to TGF-β1 [192]. Besides that, handling of glutathione deposits in stellate cells does not influence cellular activation [190]. A particular observation is that culture-induced stellate cell activation determines the accumulation of glutathione, while in vivo activation does not [193]. By adding N-acetyl-L-cysteine (NAC) to stellate cells, the cellular glutathione levels are restored, which stops the stellate cell cycle and leads to the initiation of p21, a cell cycle-dependent kinase inhibitor, which promotes cell cycle arrest [194].

HSCs are equipped with regulated systems that evaluate cellular pH [195], which are associated with cellular activation [2]. Particularly, the principal intracellular (pH) modulator in rat stellate cells is the Na+/H+ exchanger [2]. During HSCs activation, pH, and PDGF-stimulated activity of the Na+/H+ exchanger increase [195, 196].

There are a wide range of reports that reveal the crucial role of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) in regulating some pathways with a very important role in stellate cell activation, such as reactions to angiotensinogen II and PDGF, apoptosis of cellular debris, and production of oxidative stress [197]. A characteristic feature is that stellate cells express essential parts (p22phox, gp91phox, p47phox, and p67phox) of a nonphagocytic type of NOX that generates superoxide [198]. During stellate cell activation, the nonphagocytic form of NOX is initiated and produces superoxide by connecting angiotensinogen II (ANG II) to its receptors [199]. It seems that ANG II signaling is responsible for the phosphorylation of the p47 subunit of NOX, enhanced superoxide secretion, and stellate cell activation, reactions that are dulled in p47−/− mice [199]. It was shown that these mice had decreased fibrosis following liver insult due to BDL, confirming the biological role of this pathway.

Another interesting finding is that the phagocytic role of stellate cells towards apoptotic bodies is also connected to NOX initiation, with enhanced oxidative stress [200]. The NOX inhibitor Diphenyleneiodonium (DPI) suppresses this reaction [200]. Furthermore, NOX regulates downstream effects of PDGF signaling, and DPI stops the proliferative effects of PDGF [198].

**Synthesis of lipoproteins, growth factors, and cytokines**

It seems that Ito cells produce molecules with autocrine and paracrine functions, like lipoproteins, growth factors, and cytokines [2]. Like various quiescent perivascular cells, HSCs produce apolipoprotein E (ApoE) [153, 201]. ApoE, the plasma lipoprotein involved in lipid metabolism, is highly expressed in quiescent vascular smooth muscle cells [202]. ApoE has an essential role in preserving hepatic homeostasis, theory supported by the fact that ApoE-deficient mice expressed enhanced TGF-β, monocyte chemoattractant protein-1 (MCP-1), and TIMP-1 in the liver when compared to wild-type (WT) mice [153, 203]. It was reported that HSCs also expressed apo A-I and apo A-IV [204].

Stellate cells also produce other types of lipids like prostaglandins (PGs). PGs have key functions in liver metabolism and inflammatory response, also as neural-mediated vasoregulation [2]. At initial phases in primary culture, stellate cells of rat quickly secrete PGF2α and PGD2 during incubation with the neurotransmitter norepinephrine or ATP [205]. In vivo, this evidence has a particular importance due to the vicinity of stellate cells to nerve terminations in healthy liver [2]. In response to ethanol stimulation, HSCs become intensively activated and secrete PGF2 and PGE2 [206]. HSCs also secrete leukotriene C4 and B4 [207]. The implications of leukotriene in the activity of HSCs are not completely elucidated [2].

HSCs secrete a wide range of growth factors and cytokines in the liver [2]. It seems like for every growth factor, stellate cells not only produce cytokines but also react to them, accenting the value of closely mediated local control of cytokine activity within the pericellular environment [2]. Stellate cells produce two strong epithelial growth factors, transforming growth factor-alpha (TGF-α) and EGF, that have key functions in hepatocyte proliferation during hepatic regeneration [127, 208, 209]. Moreover, TGF-α and EGF promote the mitotic activity in stellate cells [2]. HGF is a stronger hepatocyte mitotic factor generated by stellate cells [125, 210]. During acute hepatic insult, the secretion of HGF by stellate cells is reduced [125]. Stellate cells also secrete stem cell factor (SCF) in rats during liver regeneration initiated by PH combined with 2-AAF [211]. Furthermore, Ito cells secrete insulin-like growth factor (IGF) I and II [212, 213]. In addition, HSCs produce the strongest mitotic factor, PDGF, a dimer composed of two subunits A- and B-chain [214–216]. PDGF A-chain mRNA has been found in activated human HSCs [217]. Stellate cells produce high levels of PDGF and show also enhanced upregulation of PDGFRs, during hepatic insult [83, 218]. A fascinating model emphasizing the role of PDGF in liver is one in which a mouse with transgenic expression of PDGF-C induces the fibrogenesis process, and promotes HCC development [2, 219]. In tardive hepatic development and during liver regeneration, stellate cells in situ secrete acidic fibroblast growth factor (aFGF), another mitotic factor [2, 220].

Stellate cells secrete macrophage colony-stimulating factor (M-CSF) and MCP-1 [221], which modulate macrophage accumulation and growth [2]. The synthesis of these macrophage growth factors could be involved in the intensification of the inflammatory and fibrogenic reactions during hepatic injury [2]. Also, HSCs promote the neutrophil inflammatory response in injured liver by secreting platelet-activating factor (PAF) [2]. PAF favors the recruitment of neutrophils and promotes their activation [222]. It was revealed that during experimental fibrosis, PAF and its receptors are initiated on stellate cells [223]. Stellate cells generate numerous chemokines, such as
cytokine-induced neutrophil chemoattractant (CINC), a rat variant of human IL-8 [224], regulated upon activation, normal T-cell expressed and presumably secreted (RANTES) [170], C-X-C chemokine ligand 1 (CXCL1) [225], macrophage inflammatory protein-2 (MIP-2) [225] and others [226].

Stellate cells could increase the acute phase response by producing IL-6 [227, 228]. On the other hand, stellate cells also secrete anti-inflammatory cytokines like follistatin and IL-10 [2, 153]. Both cytokines have antifibrotic roles [2, 153]. It was demonstrated that rats exposed to CCl4 and treated with follistatin presented low liver fibrosis and reduced HSCs proliferation [153]. IL-10 represents a hepatoprotective cytokine with an important antifibrotic role by decreasing collagen I expression while increasing interstitial collagenase [2]. This role of IL-10 is supported by the observation that IL-10-deficient mice acquired increase liver fibrosis after CCl4 administration [229].

Stellate cells also display various adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1) [230], vascular cell adhesion molecule-1 (VCAM-1) [231], and neural cell adhesion molecule (NCAM) [232–234]. ICAM and VCAM may have a role in recruitments of inflammatory cells during liver injury [2]. Stellate cells showing NCAM have been detected in the vicinity of nerve terminations in the liver [232].

Stellate cells secrete TGF-β1, one of the most crucial cytokines after liver injury [2]. This cytokine is produced in a latent form in reaction to injury, and following its activation, has strong fibrogenic properties in both autocrine and paracrine forms, especially autocrine [2]. It was reported that TGF-β1 was enhanced in experimental and human liver fibrosis [2]. There are several processes regulating the activation of latent TGF-β1 like cell surface activation after binding to cell-surface mannose-6-phosphate/IGF-II receptor [235] or binding to several proteins secreted by stellate cells [236], including α2-macroglobulin [237], decorin, and biglycan [2]. In addition, local plasminogen activator (PA)/plasmin is involved in the activation of latent TGF-β1 [2].

Furthermore, Ito cells produce a growth factor regulator protein, connective tissue growth factor (CTGF) protein that favors fibrogenesis in skin, lung, and kidney. This cytokine is very increased during liver fibrogenesis [2].

Stellate cells represent an important source of endothelin-1 (ET-1) during liver injury [2]. ET-1 is a strong vasoconstrictor, which could be responsible for portal hypertension in the cirrhotic liver due to its contractile role on stellate cells and MFBs [238, 239]. Also, ET-1 favors the proliferation of early-cultured stellate cells and suppressed those completely activated [240]. On the other hand, stellate cells represent the source of nitric oxide (NO), a physiological opponent to ET-1 [241]. NO could be involved in the sustainment of microcirculation during hepatic insult [2].

In addition, stellate cells produce cystatin C [242], a serum protein filtered by the kidney and used as a sensitive marker of glomerular filtration rate [243].

The involvement of HSCs in liver pathology

Due to their key roles in normal and injured liver, stellate cells have been characterized in numerous human diseases [2] like alcoholic steatohepatitis (ASH) [244, 245], NAFLD [2, 19, 153], hepatitis B virus (HBV) or HCV infection [19, 65, 246–253], HCC [2, 130, 254–257], cholangiocarcinoma [254], vascular disease [258], hematological malignancy [258], biliary disease [258], mucopolysaccharidosis [259], Acetaminophen overdose [260], leishmaniasis [19, 261] and schistosomiasis [19]. In this review, we discuss their behavior in the context of liver fibrosis, viral hepatitis, and liver tumors.

From normal to a fibrotic liver

The liver represents a complex organ with multiple functions like biosynthesis, metabolism, clearance, and host defense [262]. The particular and various structural and cellular composition of the liver are responsible for these specific functions [262].

From a structural point of view, the liver is composed of five components: (i) hepatocytes and hepatic lobules; (ii) vascular system; (iii) hepatic sinusoids, which usually develop into lymphoid tissue; and (iv) biliary tract and (v) stroma [257, 263]. Hepatocytes and cholangiocytes are parenchymal cells with glandular, metabolic, and detoxifying roles [262]. They represent 70% of totally cells in the liver [262]. The remaining cells are the NPCs, that occupy the 30% of the liver and include endothelial cells, Kupffer cells, stellate cells, and lymphocytes [257, 262]. All of them have systemic and local functions [262]; systemically, these specific cells are involved in blood filtration, molecular cleaning, also in inflammatory and immune responses, and locally they ensure the liver microcirculation, ECM structure and, in addition, liver tissue replacement and regeneration [262, 264].

During hepatic injuries, the liver histological structure is replaced with a scar tissue [257]. During the fibrotic process, the liver parenchyma is permanently replaced with abnormal regenerative nodules, separated by rich collagen bundles, secreted by activated Ito cells [265].

Fibrosis is the main pathophysiological result of chronic liver injury and represents the most frequent path responsible for liver failure and for most of the clinical complications of end-stage liver disease [28].

Liver fibrosis and HSCs activation

Fibrosis represents an active and permanent process that takes place in response to a chronic injury and affects the homeostasis of the ECM [28, 43]. The most common types of fibrotic liver disorder are ALD, NAFLD, which usually develops into non-alcoholic steatohepatitis (NASH) [266], and viral hepatitis [43].

Fibrosis refers to an abnormal accumulation of fibrillar ECM components, like collagen I and III, in the space of Disse [267, 268]. The accumulation of ECM components in the space of Disse is responsible for the impairment of the normal, fenestrated liver sinusoids in a process defined as capillarization of these vessels [28, 268, 269]. These alterations affect the normal nutrient transport between sinusoidal blood and neighboring cells, particularly hepatocytes, inducing functional perturbation...
The fibrotic process is associated with immune infiltrations and changes in angiogenesis [43]. All these processes are responsible for the disruption of the normal liver architecture, for the liver elasticity loss, and finally for the alteration in organ structure and function [43, 270].

The main cell type involved in liver fibrogenesis is represented by HSCs [2, 28, 43, 153, 271]. In response to hepatic injury, Ito cells become activated, and they convert from inactive rich vitamin A cells into MFB-like cells with proliferative, contractile, migratory, and fibrogenic properties [2, 28, 42, 43, 45].

During activation, they lose their specific lipid droplets, gain a fibroblast-like shape, and express high levels of α-SMA (Figures 1 and 2) and ECM elements [2, 28, 42, 43, 153, 268]. Furthermore, activated stellate cells are rich in rough endoplasmic reticulum, associated with a well-formed Golgi apparatus and development of many microfilaments bundles beneath the cell membrane [2, 19, 28, 42, 43, 153, 268]. Activation of HSCs happens in three stages: initiation, perpetuation, and resolution [2, 28, 42]. Initiation is characterized by the initial modifications in gene expression and morphology that make the cells responsive to other cytokines and stimuli [2, 28, 42, 43]. The second phase, perpetuation, is the result of the stimuli effects on sustaining the activated phenotype and producing fibrosis. Perpetuation includes proliferation, contractility, fibrogenesis, matrix degradation, retinoid loss, and inflammatory cell infiltration [2, 28, 42]. The third phase, resolution of fibrosis, comprises pathways that either promote stellate cell apoptosis, or lead to their return to the quiescent form [2, 28, 42]. During these phases, HSCs are stimulated in an autocrine and paracrine manner by various cytokines and growth factors produced by several liver resident cell types, such as Kupffer cells, hepatocytes, platelets, lymphocytes, and SECs [19, 28, 153].

The best analyzed mediators that activate HSCs include PDGF, TGF-β, cell surface death receptor (Fas), apoptotic bodies, extracellular vesicles (EVs), and stiffness [2, 153, 272, 273]. These mediators are secreted by various cell types like SECs [272], Kupffer cells [274], injured hepatocytes [275, 276], and HSCs [277].

In liver injury, Kupffer cells can influence the activation and proliferation of HSCs through cytokine secretion, including TGF-β1, IL-1, TNF-α, reactive oxygen species (ROS), and lipid peroxides [2, 43, 45]. Also, Kupffer cells promote HSCs migration by secreting PDGF [42, 153]. Moreover, Kupffer cells produce MCP-1 in a sphingosine kinase-1 (SK-1)-dependent fashion [278]. MCP-1 connects to C–C motif chemokine receptor 2 (CCR2), which is expressed in both HSCs and Kupffer cells, causing their migration [278, 279] and finally hepatic fibrosis [280]. It was shown that mice treated with a specific inhibitor of SK-1 did not develop liver fibrosis in CCl4- and BDL-induced liver injuries [153, 278].

Hepatocytes, the main hepatic parenchymal cells, also contribute to the activation of HSCs [19, 43, 153]. It seems that damaged hepatocytes undergo apoptosis by a Fas-dependent mechanism and elaborate apoptotic bodies, which are swallowed by HSCs [275, 276]. This process promotes the fibrogenic activity of HSCs through the enhanced production of collagen α1, TGF-β1, and α-SMA [153, 276]. In addition, injured hepatocytes elaborate ROS and lipid peroxides, which activate HSCs and cause hepatic fibrosis [42, 153, 281].

Another cell type involved in HSCs activation is activated or capillarized SECs [19, 28, 43, 153]. Capillarized SECs stimulate HSCs contraction by increasing ET-1 secretion and decreasing NO liberation [42, 153, 272]. SECs promote HSCs migration through the secretion of SDF-1/C–X–C motif chemokine ligand 12 (CXCL12) [153, 282] and the liberation of SK-1-containing EVs [153, 283]. Also, in liver fibrogenesis, SECs modulate fibroblast growth factor receptor 1 (FGFR1) and C–C motif chemokine receptor 4 (CXCR4) expressions, consolidating the fibrogenic phenotype of HSCs [153, 284].

Platelets also are involved in HSCs activation by secreting pro-fibrogenic growth factors like PDGF, TGF-β1 and EGF [19, 20, 285]. Furthermore, neutrophils are also responsible for the activation of stellate cells by secreting ROS [2, 19, 43, 45]. Also, it seems that lymphocytes may generate pro-fibrogenic cytokines [43].

Along SECs, Kupffer cells, hepatocytes, platelets, leukocytes, activated HSCs can also generate pro-fibrogenic cytokines, growth factors, and morphogenetic proteins, which in turn modulate and alter tissue architecture [153]. It is known that activated HSCs produce pro-fibrogenic molecules like Collα1, TGF-β1, and PDGF-BB [2, 153, 286]. In addition, the reduction of RA level in HSCs leads to the initiation of TGF-β1 expression and activation of HSCs, supporting the contribution of RA in HSCs quiescence [153, 287].

It was established that bacterial LPS, has a key function in the reduction of RA signaling through the initiation of the autophagy of HSCs lipid droplets and determining the HSCs activation [153, 288]. HSCs activated by LPS initiate the secretion of interferon-beta (IFN-β), which favors hepatocyte apoptosis [153, 289]. Successively, apoptotic hepatocytes are involved in the activation of HSCs [153, 275, 276].

Additionally, activated HSCs and MFBs represent the source of a strong angiogenic factor, VEGF, which binds to VEGFR expressed by SECs and initiates angiogenesis in the context of fibrosis [153, 290].

It was reported that activated HSCs generate PDGFRα-enriched EVs, which have a paracrine role in stimulating in vitro cell migration and in vivo fibrogenesis [153, 277]. The PDGFRα enrichment in HSC-derived EVs is associated with Src homology-2 domain-containing protein tyrosine phosphatase-2 (SHP2) and it seems like hepatic fibrogenesis was highly decreased in mice treated with SHP2 inhibitor, SHP099 [153, 277].

A surprising finding is that G protein-coupled receptors (GPCRs) are rising as new perspectives in hepatic fibrosis [153]. It seems like activated stellate cells express protease-activated receptor-2 (PAR2) [153] and proliferation of HSCs and collagen accumulation were reduced by suppressing PAR2 with PZ-235 [153, 291].

Another factor involved in the activation of stellate cells is hepatic stiffness [28, 153]. This role is suggested by the fact that freshly isolated Ito cells placed on a tender substrate, preserve their lipid droplets and increase...
concentrations of PPARγ [153]. In contrast, HSCs drop off their lipid droplets and upregulate α-SMA and collagen I expression, when are placed on a stiff substrate [292]. Furthermore, recently it was shown that substrate stiffness initiates HSCs’ activation by translocation into the nucleus of histone acetyl transferase p300, which is responsible for the upregulation transcription of HSCs’ activation genes [153, 273].

Activated HSCs predominantly secrete collagens type I and III and ECM proteins like fibronectin, thrombospondin-1 and proteoglycans [43]. Ito cells secrete collagen in the form of pre-procollagen [43]. In addition, activated stellate cells express and modulate the actions of various families of ECM regulatory factors. The main enzymes secreted by stellate cells are lysyl oxidase (LOX), lysyl oxidase-like (LOXL) proteins, and transglutaminase, responsible for the regulation of crosslinking of collagen in the extracellular space [43, 293–295]. HSCs expressed tissue inhibitors, including adamalysins [A disintegrin and metalloproteinasises (ADAMs)] and ADAM with thrombospondin motifs (ADAMTS)], meprins, etc., which may suppress the actions of MMPs, involved in the degradation of ECM at physiological pH [43, 296].

It is well known that activated stellate cells express α-SMA, an authentic marker of HSCs activation [2, 19, 28, 42, 43]. Quantitative study of HSCs’ activation using α-SMA has been demonstrated to be a helpful prognostic marker in evaluating the evolution of liver fibrosis in some hepatic diseases [28]. It was revealed that during activation, the levels of microRNA (miRNA) levels are modified [19, 297, 298]. A new microarray study of human quiescent HSCs revealed 47 downregulated and 212 upregulated miRNAs [19, 299]. It was demonstrated that let7A and let7B miRNAs modulate HSCs activation in reply to LPS and TGF-β [19, 300]. Overexpression of let7A and let7B suppressed myofibroblastic activation of HSCs as evident by downregulation of actin alpha 2 (ACTA2), collagen type I alpha 1 (COL1A1), TIMP-1 and fibronectin-1 (FN1) [19, 300]. In the same manner, there was enhanced expression of miR-27a and miR-27b in activated HSCs, and their downregulation was responsible for the decreased HSCs proliferation and increased in lipid droplets showing that miR-27a and miR-27b could have a trigger role in HSCs quiescent phenotype [19, 301]. In addition, it was established that miR-27a and miR-27b directly targeted the 3'-untranslated region (3'-UTR) of retinoid X receptor-alpha (RXRa) to suppress its expression in HSCs reducing DNA synthesis and, consequently, cell proliferation [19, 45, 302].

**HSCs in viral hepatitis B and C**

Viral hepatitis B (HBV) and C (HCV) are liver diseases that can lead to cirrhosis, liver failure and HCC [303]. They are the most frequent infectious diseases responsible for human liver diseases, including acute, fulminant, and chronic hepatitis [303]. HBV infection is still a crucial worldwide health issue, as it affects more than 350 million people chronically and kills approximately 600 000 people every year [304]. In HBV, the proliferation of the healthy population of HSCs is increased by PDGF and TGF-β [305–307] and is decreased once they get infected with the extracellular virus [304]. It was reported that hepatitis B virus X protein (HBx) is responsible for the activation of human HSCs by upregulating TGF-β1 [307, 308]. Thus, HBx may stimulate hepatic fibrosis by supporting HSCs proliferation and upregulating the expression of fibrosis-associated molecules [271, 307, 308].

It seems that during chronic HBV infection activated Ito cells secrete IL-6 and IL-1β, leading to T-helper 1 (Th17) cells activation [19]. IL-17 generated by the Th17 cells stimulates stellate cells through IL-17 receptor (IL-17R), contributing to upregulation of profibrogenic factors, such as IL-6, TGF-β, α-SMA and collagen I [309, 310], supporting the fact that IL-17 has a key role in liver fibrosis [19]. In the same manner, IL-22 also is involved in HCV-related fibrosis through the activation of HSCs [19]. Also, IL-22 is responsible for LX-2 cell proliferation, overexpression of α-SMA and up-regulation of collagen synthesis by LX-2 cells [311].

A study conducted by Lotowska & Lebenszejn revealed that HSCs in children with chronic hepatitis B exhibited a tight positive correlation between the cell count and the severity of fibrosis, concluding that they have prognostic roles in this disease [253].

Chronic viral hepatitis C affects around 3% of world population [251]. It seems that C viral proteins regulate apoptosis and steatosis, finally leading to HSCs activation, fibrogenesis and hepatocarcinogenesis [251]. At first, the immune cells try to eliminate the virus, but in the background of chronic infection, perhaps they induce hepatocyte impairment and fibrosis by direct cellular toxicity and by producing inflammatory cytokines [251, 312, 313]. It seems that several patients with chronic hepatitis C will undergo cirrhosis rapidly (“fast fibrosers”), several will develop cirrhosis slowly (“slow fibrosers”) and the remainders are named as “intermediate fibrosers” [251]. It is well documented that HSCs have a crucial role in the process of fibrosis and its progress to cirrhosis [51, 314, 315]. In case of stress and injury, like in chronic viral hepatitis C, HSCs become activated and develop myofibroblastic features, producing increased ECM accumulation [251].

HCV activates HSCs in a direct or indirect way, promoting fibrogenesis [316]. It was reported that E2 protein of HCV directly binds CD81 existing on the surface of Ito cells [317]. Moreover, the interaction between HCV core proteins, NS3-NS5 and HSCs lead to the initiation of pro-inflammatory cytokines including RANTES, MCP-1, and IL-8 [318]. In addition, double-stranded RNA (dsRNA) could stimulate HSCs activation by TLR3 leading to the secretion of type 1 IFNs (IFN-α/β) [319]. Also, retinoic acid-inducible gene 1 (RIG-I), a cytoplasmic detector of viral RNA, was involved in the activation of LX-2 cells (HSCs) generating type 1 IFN (IFN-β) and type III IFN (IFN-γ) [319].

A recent study conducted by Shahin et al. revealed that carboxyl and amino termini of HCV core protein could activate HSCs [320]. It was shown that HCV-infected hepatocytes can indirectly activate stellate cells through TGF-β1 and other profibrogenic factors [321]. HSCs have the property to enclose by phagocytosis apoptotic bodies, released from infected apoptotic...
hepatocytes, which triggers a profibrogenic response [200, 322]. In addition, activated Ito cells are responsible for the elaboration of IL-1α, which successively induce HCV-infected hepatocytes, leading to the initiation of proinflammatory cytokines and chemokines like IL-6, IL-8, MPL-1α and MPL-1β [323]. Furthermore, other reports have revealed indirect activation of stellate cells through ubiquitin carboxy-terminal hydrolase L1 (UCHL1), a new protein generated from HCV-infected hepatocytes involved in the activation of c-Jun N-terminal kinase (JNK) signaling leading to the overexpression of α-SMA and later activation of HSCs [324]. It was reported that IL-18, a component of the IL-1 family, supports the proliferation of HSCs, during HCV infection by modulating the activation of c-Jun levels [325]. It was demonstrated that quantitative assessment of activated HSCs, by immunohistochemistry, could be a helpful marker in prognosticating the development and evolution of liver fibrosis in patients with recurrent hepatitis C after liver transplantation [28, 326]. Many studies conducted on viral hepatitis [246–250] and livers with severe necrosis [2, 327, 328] revealed the morphology and the IHC profile of stellate cell activation. Using the α-SMA IHC marker, several studies revealed that the number of activated HSCs increased, due to the severity of chronic hepatic lesions in HCV-infected patients, pointing to a strong correlation between HSCs activity, liver fibrosis and necroinflammatory activity [250, 327–331]. On the other hand, there are authors who did not find a relationship between activated HSCs and necroinflammatory activity, probably because most HSCs were directly activated by HCV, while necroinflammatory activity only played a secondary role [250, 251, 326].

The role of HSCs in liver tumors

HCC and intrahepatic cholangiocarcinoma (ICC) are the most frequent forms of primary liver tumors [254]. Furthermore, the liver is the organ most affected by metastasis, after lymph nodes, for the main cancers, including gastrointestinal cancers, breast and prostate carcinomas, uveal melanoma, neuroendocrine tumors, and sarcomas [254, 262, 332–335]. Also, metastases are more frequent than primary liver tumors [254, 336, 337]. The tumor microenvironment (TEM) has a key role in the development of liver tumors [254]. TEM is also known as stroma, and essentially is composed of the ECM and stromal cells [254, 257]. Under physiological conditions, stroma ensures the tissue homeostasis and prevents tumor development; even so, when a cell becomes malignant, its supporting matrix changes in a manner to sustain tumor development [254, 257, 338, 339]. This changed stroma that supports cancerous cells is named TEM [257, 340]. TEM is composed of fibroblasts, MFBs, SECs, Kupffer cells, HSCs, immune and inflammatory cells, and the ECM components [254, 257, 338, 341]. The mutual crosstalk between all these TEM components lead significantly to tumor progression [254]. It seems like HSCs have a crucial role in the TEM crosstalk [254].

Regarding the fact that HSCs stimulate and influence the production of cytokines and growth factors which regulate liver proliferation and regeneration, in several clinical situations, their increased activation led to liver malignancies, like HCC and ICC [254].

The role of HSCs in HCC

HCC is one of the most fatal and common tumors in the human population [254, 256, 257, 336, 342]. HCC represents the main primary liver tumor and the fourth leading cause responsible for cancer deaths in the whole world [254, 336, 342]. It is responsible for 90% of whole cases of primary hepatic tumors [343]. The main etiology for HCC is chronic infection with HBV or HCV [254, 256, 257]. Other etiological factors are alcohol abuse, autoimmune hepatitis, and NASH [254, 257]. Persistent inflammation from time to time alters the hepatocytes DNA in a regenerating liver, thereby maximizing the occasion of gene modification, leading to carcinogenesis [254]. It is well established that the majority of HCC occurs after a chronic liver injury, and subsequently liver cirrhosis represents the principal risk factor for generating HCC [254, 257].

The evolution of HCC is controlled by the liver microenvironment [254, 256, 257]. Activated HSCs represent the main elements of the HCC microenvironment and have a crucial role in the development and progression of HCC through the production of growth factors, cytokines, ECM and MMPs [153, 254, 256, 257, 262]. Also, they promote tumor neoangiogenesis and immune-suppression [153, 254, 256, 257, 262]. It is well established that activated Ito cells infiltrate the stroma of HCC and peritumoral tissue and are found around tumor sinusoids, fibrous septa and the tumor capsule [130, 254, 256, 257, 344]. In addition, activated HSCs have been found around the periphery of dysplastic nodules within the liver [256, 345]. After activation, HSCs produce increase quantity of ECM proteins into the stroma [256]. The accumulation and degradation of fibrotic matrix by stellate cells is closely modulated in the liver [256]. Thus, TIMP-1 secretion promotes scar accumulation through suppression of endogenous matrix-degrading activities of different MMPs [256]. HSCs generate proteolytic enzymes that influence the ECM turnover, such as tissue inhibitor of metalloproteinase-2 (MMP-2/TIMP-2) and A disintegrin and metalloproteinase domain-containing protein 9 (ADAM-9) [262]. Furthermore, the elevation of TIMPs increases ECM accumulation, which promotes the progression of HCC [254]. Another interesting finding is that the biomechanical features of the ECM also contribute to the evolution of HCC [256]. There are evidences that in vitro increasing matrix stiffness promotes the growth of the HCC cell lines, HuH-7 and HepG2, and decrease the apoptosis related to chemotherapy [256, 346]. In addition, stromal stiffness is responsible for stellate cell activation, leading to fibrosis [256]. It seems that mechanical tension supported by a modified ECM may promote HCC development and progression by external signals, like integrins, which provide tumor growth and evolution [256].

Integrins mediate the crosstalk between HSCs and HCC cells [256]. Integrins represent a family of transmembrane receptors that ‘incorporate’ the extracellular and intracellular domains by connecting the ECM and the cytoskeleton [256, 347]. Thus, integrins modulate cell adherence, disseminating, migration, proliferation, and differentiation, even ECM accumulation and remodulation [256, 348]. It seems that in activated stellate cells down-
stream integrin signaling, through FAK-phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway, stimulates ECM accumulation [349]. In vitro studies revealed that the expression and activity of integrins and focal cohesivity are increased by enhanced ECM stiffness, leading to the activation of downstream integrin signals within the hepatocyte, that could favor the development and survival of preneoplastic cells [256]. Evidences have shown that softer matrices abolished hepatoma growth and stiffer matrices favored proliferation, suggesting that matrix stiffness influences differentiation and chemotherapeutic opposition of human HCC cell lines [346, 350]. Another study revealed that HSCs cultured on a stiff medium elicited a higher tumor development compared to HSCs cultured on soft environment [273], supporting the contribution of stiffness in tumor evolution [153].

Studies in human HCC and murine HCC models highlighted connections between collagen expression, integrin expression and tumorigenicity [256, 351, 352]. Analysis of integrin expression in HCC cell lines have shown a high grade of inhomoegenity in integrin expression [353]. A study conducted by Lai et al. using two clinically pertinent mouse models of HCC, PDGF-C overexpression and Pten−/− null mice, established that each model had a characteristic type of integrin gene expression, ultimately showing the heterogeneity of HCC biology [352].

β1 Integrin subfamily has been intensively analyzed in HCC; hepatocarcinogenesis is associated with increased expression of integrins α1β1, α2β1 and α3β1 and the acquirement of a migratory phenotype by hepatocytes [256]. In addition, it was established a positive association between integrin β1 expression in human HCC tissues and ECM stiffness, histological tumor grade and metastasis [354]. It seems like the inhibition of integrin β1 in vitro importantly abolishes migration and invasion of HCC cell lines elicited by TGF-β1 and EGF [355, 356]. In contrast, enhance of integrin β1 has been reported to increase the migration of HepG2 cell [357]. A study conducted by Dong et al. using a strong-stiffness gel to culture HCC cell lines, discovered that VEGF expression is inhibited by treatment with an integrin β1-specific antibody [350]. Other integrin subunits have been found to have a major contribution in the evolution of HCC [256]. For example, Fan et al. have demonstrated that integrin α6 expression is strongly associated with HCC in humans [358]. It has been reported that superexpressed integrin α6 can form a complex with CD151, a tetraspanin protein, which promotes HCC invasion, and the PI3K–Akt signaling pathway, leading to increased epithelial-to-mesenchymal (EMT) of HCC cell lines [358]. Furthermore, evidences have shown that the suppression of integrin α3 on HCC cells abolished the anti-apoptotic role of laminin-332 [359]. Also, the expression of neuropilin-1 by HSCs-derived MFBs supported the production of fibronectin, promoting the TEM stiffness and leading to increased tumor growth [360].

It seems like the crosstalk between integrins and TGF-β signaling is also involved in hepatocarcinogenesis [256]. It has been shown that the HCC cell invasiveness was stimulated by the activation of TGF-β receptor inhibitor (RI) through phosphorylation of the intracellular component of the β1 subunit of the integrin α5β1 by Smad-2 and Smad-3, leading to an inside-out conformational modification and promoting vascular invasion [361]. Moreover, the interconnection between integrins, growth factor receptors and ECM proteins like collagen, have demonstrated to modify downstream signal activity pathways like Smad, favoring hepatocyte proliferation and preserving HSCs activation [362, 363].

Activated HSCs promote tumor cell proliferation, migration, and invasion by production of a wide range of growth factors and cytokines, including TGF-β/1, HGF, PDGF, SDF-1, VEGF, and CXCL12 [273, 360, 364–367], and by downregulating other molecules like endostatin [368]. It seems that tumor cell invasion and proliferation were stimulated by conditioned media of activated stellate cells in vitro [153, 364, 365] and in vivo [153, 273]. Furthermore, it was observed that co-incorporating stellate cells with HCC cells into the nude mice amplified the tumor development and invasiveness by activating NF-κB and extracellular signal-regulated kinase (ERK) signaling pathways [257, 365, 369]. Moreover, microarray examinations have shown the activation of some genes of inflammation, MMPs, chemotaxis and angiogenesis, succeeding the co-implantation of hepatic tumoral cells with activated stellate cells [370].

Studies using a co-transplant model of HCC cells and HSCs revealed that TGF-β signaling intrusion diminished the growth of HCC in vivo [254]. Also, TGF-β was regularly secreted in an autocrine fashion by HCC cells [371–373]. It was reported that HSCs stimulated EMT in HCC cells by TGF-β3 [374]. Thus, TGF-β plays a key role in the interaction between HCC cells and stellate cells [254].

It seems that the downregulation of the expression levels of TGF-β receptors in HCC compared with those in the neighboring normal tissues demonstrated the significance of TGF-β signaling in the induction of HCC [375]. Moreover, this downregulation was responsible for an increase tumor growth and a higher proliferation ability [375]. It was reported that the gene expression changes were also detected in co-Smad subunits [257]. For example, in HCC tissues the expression of Smad-4 was amplified and its small interfering RNA (siRNA)-mediated inhibition, suppressed the colony development in Huh7 and PLC cell lines [376]. Hepatic tumor-initiating cells could be originated from hepatic progenitor cells, chronic stimulated by TGF-β in cirrhotic liver [377]. It was shown that hypoxic hepatocytes produce enzymes that activate dormant TGF-β; hypoxia stimulates EMT in hepatocytes in a TGF-β-dependent way [377].

TGF-β stimulates the growth of a TEM by producing cancer-associated fibroblasts (CAFs), which generate growth factors and cytokines [378–380]. Furthermore, TGF-β activates HSCs into MFBs [254]. Another growth factor secreted by stellate cells and involved in tumor cell invasion and metastasis is HGF [256]. It is known that HGF controls cell proliferation, migration, survival and angiogenesis [256, 381, 382]. It seems that HGF fixes to its receptor, c-MET, leading to a phosphorylation cascade [256]. It was shown that 20–48% of HCCs contain a transmembrane receptor tyrosine kinase, c-MET, which is expressed by numerous HCC
Cisplatin, reaction regulated the HCC cell line Hep3B to the chemotherapeutic agent c-MET signaling has been proven to increase HCC signature of HCC cells has been associated with a poor prognosis, reduced 5-year survival and an aggressive phenotype of HCC [385, 386]. Also, activation of HGF/c-MET signaling has been proven to increase HCC chemoresistance [256].

It was shown that conditioned media collected from the activated HSCs cell line LX-2 increased resistance of the HCC cell line Hep3B to the chemotherapeutic agent Cisplatin, reaction regulated via HGF [387]. Neoplastic cells could also amplify prometastatic c-MET signaling through an autocrine pathway including TIMP-1, leading to downstream expression of metastasis-promoting genes [388, 389].

Evidence have shown that LPS and the gut microbiome also promote hepatocarcinogenesis [153, 256]. It was observed that LPS and the gut microbiome can initiate HSCs activation, leading to the secretion of the mitotic factors HGF and eiregulin, which probably act on tumoral hepatocytes [256]. It is known that eiregulin represents a component of the EGF family and leads to the activation of EGF receptor and human epidermal growth factor receptor 2 (HER2) during initial phases of Diethylnitrosamine (DEN)/CCl₄ carcinogenesis, whereas it decreases hepatocyte apoptosis via NF-κB nuclear translocation during advanced phases [390, 391].

Another crucial role of HSCs in HCC growth, evolution, and metastasis is the induction of angiogenesis [254, 256, 257, 262]. In order to develop, neoplastic hepatocytes need new vessel generation, initiated by numerous proangiogenic factors [256]. It seems that these pro-angiogenic factors promote tumor evolution and metastasis [256].

It is well known that activated stellate cells generate numerous angiogenic factors, such as VEGF, PDGF, MMPs, FGF, TGF-β1, EGF, angiopoietin-1 (Ang-1) and Ang-2 [392–394]. Moreover, Ito cells exhibit angiogenic growth factor receptors, like VEGFR, PDGFR and Tie2 [256]. In hepatic insult and HCC, this simplifies mutual signaling between stellate cells and endothelial cells or tumoral hepatocytes and favors a pro-angiogenic microenvironment. It was observed that during the co-implantation of HSCs with HCC cells, HCC cells increase the expression of pro-angiogenic genes (VEGF-A and MMP-2) in HSCs, as well as their proliferation and migration [395].

In vitro studies have reported that VEGF enhances endothelial cells migration, stimulates their proliferation, and diminishes apoptosis, all phases being mandatory for new vessel development [262]. Furthermore, mutually in vitro and in vivo researches have reported that the secretion of VEGF is stimulated by hypoxic situations, a usual feature of the TEM [262]. Also, it seems like activated stellate cells initiate vascular tube development by liver SECs and vascular endothelial cells. In addition, they intensely accumulated matrix laminin, which favors both tumor survival and evolution through EMT, and is also involved in synthesis of the basement membrane that for the new vessels [262].

A research conducted by Lin et al. using a murine HCC cell line and rat colon microvascular endothelial cells, observed amplified angiogenesis by activated HSCs in vitro [396]. Lin et al. also revealed, by utilizing an orthotopic HCC model, that activated HSCs stimulate tumor angiogenesis by enhanced VEGF and probably PDGF production [396]. An interesting finding in HCC is the crosstalk between tumoral hepatocytes, endothelial cells and activated HSCs. It has been described the increased expression of Ang-1, Ang-2 and Tie2 receptors in cultured HCC cell lines (HLE and HuH-7) and in human HCC specimens [397]. This study established that angiopoietin–Tie2 signaling in the vascular wall could promote vessel remodeling in HCC [396].

Ang-2 produced by HCC cells, Ito cells and smooth muscle cells fixes Tie2 receptor (expressed on HSCs, smooth muscle, and endothelial cells) and alters the contacts between endothelial cells, perivascular support cells and ECM [256]. This supports the contact with VEGF, which in these fairly hypoxic circumstances, is upregulated. All these events lead to endothelial cells proliferation, neovascularization, and tumor progression [256].

It was reported that Metformin suppresses angiogenesis in vitro, in an HCC (HepG2 line) and HSCs (LX-2) co-culture environment [398]. Tumor immune escape mechanism plays a key role in cancer evolution [256]. One path by which tumors escape the immune reaction is via the increase number and activity of immunosuppressive cells in the tumor and within lymphoid organs [399]. Such immunosuppressive cells comprise of Tregs and myeloid-derived suppressor cells (MDSCs). There are a wide range of studies that show the immunomodulatory roles of HSCs, which could encourage the existence, growth, and evolution of HCC in vitro and in vivo [400, 401].

It was demonstrated that activated stellate cells increase immunosuppressive cell populations in the HCC microenvironment by stimulating T-cell apoptosis and modifying the equilibrium of diverse T-cell populations [256]. Also, a close association between the intratumoral number of HSCs, T-cell apoptosis and lung metastatic nodules was observed in an orthotopic rat model of HCC [402]. This finding highlights the role of HSCs in HCC metastasis through an immunosuppressive way.

It was reported that co-implantation of HCC cells with HSCs in immunocompetent mice stimulated HCC proliferation and increased tumor angiogenesis, in correlation with suppression of lymphocyte infiltration and apoptosis of infiltrating monocytes [256].

A study conducted by Zhao et al. revealed, in an orthotopic liver tumor mouse model, that HSCs have an immunosuppressive function for HCC via initiation of Tregs and MDSCs, perhaps due to activation of cyclooxygenase-2 (COX2)-PGE2–EP4 signaling pathway [403]. Furthermore, it seems that activated HSCs suppress antitumor cytotoxic T-cells, therefore defending the hepatic tumor. Tumor-related HSCs stimulate DC-derived immunoglobulin receptor 2 (DiG2) in DCs, which ultimately suppress the inflammatory reply of T-cells [404].

In a different perspective, it is believed that tumoral hepatocytes and activated stellate cells create, together with CAFs and immune cells, a tumor-related environment in which the receptiveness of tumor cells to soluble factors
is augmented [380]. Thus, activated HSCs represent the hallmarks in tumor cell milieu creation that determines the malignancy and prognostic of the tumor event.

**Behavior of HSCs in ICC**

ICC is the next most frequent form of primary liver cancers, representing 5% of primary liver tumors [254]. It represents a destructive type of malignancy and has a worse prognosis, as therapeutic schemes against ICC are restrained [254]. Chemotherapy and radiotherapy are partially successful as ICC shows a fibrous stroma that is opposing to these treatments [254].

There are fewer reports concerning the role of TEM in ICC compared with those involving the HCC tumor milieu [254]. It seems that the desmoplastic stroma adjacent to ICC cells play a key role for the growth of ICC [254].

TEM composed of HSCs, SECs, CAFs, Kupffer cells and tumor-infiltrating lymphocytes (TILs) is responsible for the development, evolution, metastasis, and invasion of ICC. These cells promote the tumor development by producing many soluble factors [254]. It seems like these factors increase ICC cell multiplication and migration and also encourage the abnormal activation of other stromal cells [405, 406]. A study conducted by Sulpice et al. revealed that the stroma of ICC contains upregulated genes associated with the cell cycle, ECM and TGF-β. In addition, it was proved that the ICC prognosis is strongly associated with the stromal expression of osteopontin (OPN) [405]. It is known that osteopontin is involved in HSCs activation via TGF-β/β1. Thus, activated HSCs may contribute to ICC evolution via OPN [406].

HSCs produce SDF-1, which controls ICC cell migration and survival [407]. Furthermore, SDF-1 increases the EMT via the crosstalk between activated HSCs and the SDF-1/CXCR4 axis in ICC [408]. Also, HSCs are activated by SDF-1 in an autocrine way. It seems that in ICC, elevated expression of ECM was related with a worse prognosis [254]. One of the main ECM components in ICC is represented by HSCs. It was shown that ICC tumors displayed an elevated expression of α-SMA, a marker of HSCs, as well as significantly poor survival, in contrast to low-α-SMA-expression tumors [364, 409]. The proliferation and invasion of ICC cells were enhanced by co-implanting an ICC cell line with an HSCs line [364].

A study conducted by Kim et al. established that HSCs promote the proliferation, migration, angiogenesis, and invasion of ICC cells, induce angiogenesis by Hh signaling pathway activation, and makes ICC more vulnerable to necrosis by Hh pathway inhibitors [410]. All this evidence shows the key role of HSCs in the progression of ICC.

**Conclusions**

From past till nowadays, many findings have been made regarding these “pluripotent cells” and no one could have imagined their complex capacity when they were first discovered. HSCs represent the remarkable cells of the liver due to their ability to preserve hepatic homeostasis, development, and regeneration as well as their crucial roles in the pathogenesis of liver diseases. All of these fundamental characteristics make the HSCs a powerful therapeutic target for liver pathology. By isolating diverse HSCs subpopulations and particularly targeting the highly fibrogenic types, researchers aim to create new therapies in liver diseases. Some promising anti-fibrotic approaches aspiring the inhibition or reversal of HSCs stimulated liver fibrosis have been created [411]. In addition, Cenicriviroc, a double C–C chemokine receptor type 2 and 5 (CCR2/CCL5) antagonist, was used in phase 2 clinical trial and has been assessed in liver inflammation and fibrosis in the setting of NASH [412]. Furthermore, activated HSCs represent a main component of the TEM. Thus, they could be an important therapeutic target for hepatic tumors. For example, human monoclonal antibodies against FAP, Sibrotuzumab and Val-boroPro could be applied for targeting activated stellate cells [413, 414]. Another therapeutic strategy could be Hh signaling pathway [415]. Suppressing the Hh signaling pathway may inhibit the activation of HSCs. As our knowledge regarding HSCs and their essential involvement in liver homeostasis and pathology increases, the cure of hepatic diseases will become promising.

**Conflict of interests**

The authors declare that they have no conflict of interests.

**References**

[1] ***. Hepatic stellate cell nomenclature. Hepatology, 1996, 23(1):193. PMID: 8550043
[2] Friedman SL. Hepatic stellate cells: protein, multifunctional, and enigmatic cells of the liver. Physiol Rev, 2008, 88(1):125–172. https://doi.org/10.1152/physrev.00013.2007 PMID: 18195685
[3] Senoo H. Structure and function of hepatic stellate cells. Med Electron Microscos, 2004, 37(1):3–15. https://doi.org/10.1007/s00795-003-0230-3 PMID: 15057600
[4] Wake K. "Sternzellen" in the liver: perisinusoidal cells with special reference to storage of vitamin A. Am J Anat, 1971, 132(4):429–462. https://doi.org/10.1002/aja.1001320404 PMID: 4942297
[5] Wake K. Perisinusoidal stellate cells (fat-storing cells, interstitial cells, lipocytes), their related structure in and around the liver sinusoids, and vitamin A-storing cells in extrahepatic organs. Int Rev Cytol, 1980, 66:303–353. https://doi.org/10.1016/s0079-7469(08)61977-4 PMID: 6993411
[6] Ito T. Cytological studies on stellate cells of Kupffer and fat storing cells in the capillary wall of human liver (abstract). Acta Anat Jpn, 1951, 26:42.
[7] Bronfenbrenner S, Schaffner F, Popper H. Fat-storing cells (lipocytes) in human liver. Arch Pathol, 1966, 82(5):447–453. PMID: 5923468
[8] Kent G, Gay S, Inouye T, Bahu R, Minick OT, Popper H. Vitamin A-containing lipocytes and formation of type III collagen in liver injury. Proc Natl Acad Sci U S A, 1976, 73(10):3719–3722. https://doi.org/10.1073/pnas.73.10.3719 PMID: 1068482 PMCID: PMC431990
[9] Gutiérrez-Ruiz MC, Gómez-Quiróz LE. Liver fibrosis: searching for cell model answers. Liver Int, 2007, 27(4):434–439. https://doi.org/10.1111/j.1478-3233.2007.01469.x PMID: 17403182
[10] Martinez-Hernandez A. The hepatic extracellular matrix. I. Electron immunohistochemical studies in normal rat liver. Lab Invest, 1984, 51(1):57–74. PMID: 6376944
[11] Friedman SL, Roll FJ. Isolation and culture of hepatic lipocytes, Kupffer cells, and sinusoidal endothelial cells by density gradient centrifugation with Strachan. Anat Biochem, 1987, 161(1):207–218. https://doi.org/10.1016/0003-2697(87)90067-7 PMID: 3578783
[12] Chen W, Grendraul JL, Steffan AM, Jeandidier E, A Kim A. Isolation, culture and main characteristics of mouse fat-storing cells: interaction with viruses. Hepatology, 1989, 9(3):352–362. https://doi.org/10.1002/hep.1840090303 PMID: 2465966
Suskind DL, Muench MO. Searching for common stem cells. 

Moreira RK. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med, 2007, 131(11):1728–1734. https://doi.org/10.1043/1543-2165(2007)131[1728:HSCALF]2.0.CO;2. PMID: 17979495

Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci U S A, 1985, 82(24):8681–8685. https://doi.org/10.1073/pnas.82.24.8681. PMID: 3909149. PMCID: PMC391500

Blaner WS, O’Byrne SM, Wongsingir J, Kluwe J, D’Ambrosio DM, Jiang H, Schwabe RF, Hillman EM, Plantedo R, Libien B. Hepatic stellate cell lipid droplets: a specialized lipid droplet for retinoid storage. Biochim Biophys Acta, 2000, 1791(6):467–473. https://doi.org/10.1016/S0006-2727(99)00349-4. PMID: 11485750. PMCID: PMC6726602.

Galler K, Requardt RP, Glaser U, Markwart R, Bocklitz T, Bauer M, Popp J, Neugebauer U. Single cell analysis in native tissue: quantification of the retinoid content of hepatic stellate cells. Sci Rep, 2016, 6:24155. https://doi.org/10.1038/srep24155. PMID: 27083397. PMCID: PMC4827054.

Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol, 2017, 14(7):397–406. https://doi.org/10.1038/nrgastro.2017.38. PMID: 28497549.

Khomich O, Ivanov AV, Bartosch B. Metabolic hallmarks of hepatic stellate cells in liver fibrosis. Cells, 2019, 9(1):24. https://doi.org/10.3390/cells9010024. PMID: 31861818. PMCID: PMC7061717.

Ueno T, Mata M, Sakata R, Torimura T, Sakamoto M, Sugawara H, Tanikawa K. Hepatic stellate cells and intralobular innervation in human liver cirrhosis. Hum Pathol, 1997, 28(9):953–959. https://doi.org/10.1006/huap.1997.6511. PMID: 9269832.

Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol, 2013, 3(4):1397–1412. https://doi.org/10.1002/cphy.c120035. PMID: 24265236.
Hepatic stellate cells – from past till present: morphology, human markers, human cell lines, behavior in normal…
Nagatsuma K, Hano H, Murakami K, Shindo D, Matsumoto Y, Mukherjee P, Friedman SL, Eng FJ. Human hepatic stellate cells retain the capacity to synthesize retinyl esters and to store neutral lipids in small lipid droplets in the absence of LRAT. Biochim Biophys Acta Mol Cell Biol Lipids, 2017, 1862(2):176–187. https://doi.org/10.1016/j.bbalip.2016.10.013 PMID: 27815220

Pan XP, Yang Y, Yu XP, Li JZ, Zhou N, Du WB, Zhang YH, Gao HC, Zhu YL, Li LL. Establishment and characterization of an immortalized human hepatic stellate cell line for applications in co-culturing with immortalized human hepatocytes. Int J Med Sci, 2015, 12(3):248–255. https://doi.org/10.7150/ijms.11002 PMID: 25678842 PMCID: PMC4332363

Shirakami Y, Lee SA, Clagston RD, Blaner WS. Hepatic metabolism of retinoids and disease associations. Biochim Biophys Acta, 2012, 1821(1):124–136. https://doi.org/10.1016/j.bbapap.2011.08.023 PMID: 21763780 PMCID: PMC3488285

O’Byrne SM, Blaner WS. Retinol and retinyl esters: history, metabolism, and physiology. J Lipid Res, 2013, 54(7):1731–1743. https://doi.org/10.1194/jlr.R037648 PMID: 23625372 PMCID: PMC3679378

Schreiber R, Taschner U, Preiss-Landli K, Wongsirinong R, Zimmermann R, Lass A. Retinyl ester hydrolases and their roles in vitamin A homeostasis. Biochim Biophys Acta, 2012, 1821(1):113–123. https://doi.org/10.1016/j.bbapap.2011.05.001 PMID: 21586336 PMCID: PMC3242165

Yamada M, Blaner WS, Soprano DR, Dixon JL, Kjeldbye HM, Goodman DS. Biochemical characteristics of isolated rat liver stellate cells. Hepatology, 1987, 6(7):1224–1229. https://doi.org/10.1002/hep.184006070609 PMID: 2824313

Higashi N, Imai K, Sato M, Sato T, Kojima N, Miura M, Wold HL, Moskau JG, Berg T, Norum KR, Roos N, Wake K, Bromhoff R, Sano H. Intranuclear vitamin A-storing lipid droplets in hepatic stellate cells with special reference to polar bear and arctic fox. Comp Hepatol, 2004, 3(3 Suppl):S1; 516. https://doi.org/10.1186/1476-526-3-S1-516 PMID: 14980438 PMCID: PMC306023

Sanco H, Yoshihara Iwakawa K, Mori M, Miura M, Imai K, Mezaki Y. Hepatic stellate cell (vitamin A-storing cell) and its relative – past, present and future. Cell Biol Int, 2010, 34(12):1247–1272. https://doi.org/10.1002/cbic.20100321 PMID: 21067523

Friedman SL, Weisb. Blaner WS. Retinal release by activated rat hepatic lipocytes: regulation by Kuffer cell-conditioned medium and PDGF. Am J Physiol, 1993, 264(5 Pt 1):G947–G952. https://doi.org/10.1152/ajpgi.1993.264.5.G947 PMID: 8496521

Straub BK, Stoeffel P, Heid H, Zimmbermann R, Schirmacher P. Differential pattern of lipid droplet-associated proteins and de novo perilipin expression in hepatocyte steatogenesis. Hepatology, 2008, 47(6):1936–1946. https://doi.org/10.1002/hep.22268 PMID: 18393930

Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Banhot S, Monia BP, Li YX, Diehl AM. Diacylglycerol acyltransferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis. Hepatology, 2007, 46(2):625–635. https://doi.org/10.1002/hep.22188 PMID: 18000980

Yen CLE, Monetti M, Burri BJ, Faresse RV Jr. The triacylglycerol synthesis enzyme DGAT1 also catalyzes the synthesis of diacylglycerols, waxes, and retinyl esters. J Lipid Res, 2005, 46(7):1502–1511. https://doi.org/10.1194/jlr.M500036-6-JLR200 PMID: 15834125

Zhao C, Chen W, Yang L, Chen L, Stimpson SA, Diehl AM, PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun, 2006, 350(2):385–391. https://doi.org/10.1016/j.bbrc.2006.09.114 PMID: 17010576 PMCID: PMC1774377

Zhao C, Chen W, Yang L, Chen L, Stimpson SA, Diehl AM, PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun, 2006, 350(2):385–391. https://doi.org/10.1016/j.bbrc.2006.09.114 PMID: 17010576 PMCID: PMC1774377
Hepatic stellate cells – from past till present: morphology, human markers, human cell lines, behavior in normal...

[109] Orland MD, Anwar K, Cromley D, Chu CH, Chen L, Billheimer JT, Hussain MM, Cheng D. Acetyl coenzyme A dependent retinol esterification by acetyl coenzyme A: dicycl-glycerol acyltransferase 1. Biochim Biophys Acta, 2005, 1737(1):76–82. https://doi.org/10.1016/j.bbabio.2005.09.003 PMID: 16214399

[110] Camrona R, Barrena S, Muñoz-Chápuli R. Retinoids in stellate cells: development, repair, and regeneration. J Dev Biol, 2019, 7(2): 10. https://doi.org/10.3390/jdb7020010 PMID: 31137700 PMIDC: PMCID:PMC6630434

[111] Bobowski-Gerard M, Zummo FP, Staelens B, Lefebvre P, Eickhout J. Retinoids issued from hepatic stellate cell lipid droplet loss as potential signaling molecules orchestrating a multicellular liver injury response. Cells, 2018, 7(10): 137. https://doi.org/10.3390/cells7090137 PMID: 30217095 PMIDC: PMCID:PMC6162435

[112] Leo MA, Lieber CS. Hepatic vitamin A depletion in alcoholic liver injury. N Engl J Med, 1982, 307(10):597–601. https://doi.org/10.1056/NEJM198209023071006 PMID: 7022119

[113] Cui X, Dang S, Wang Y, Chen Y, Zhou J, Shen C, Kuang Y, Fei J, Lu L, Wang Z. Retinol dehydrogenase 13 deficiency diminishes carbon tetrachloride-induced liver fibrosis in mice. Toxicol Lett, 2017, 265:17–22. https://doi.org/10.1016/j.toxlet.2016.10.010 PMID: 27865848

[114] Yi HS, Lee YS, Byun JS, Seo W, Jeong JM, Park O, Kinnman N, Francoz C, Barbu V, Wendum D, Rey C, Duester G, Haseba T, Kim SC, Park KG, Gao B, Jeong WJ. Acyl-CoA:diacylglycerol acyltransferase III expression is regulated by enhancing stellate cell activation and suppressing natural killer cells in mice. Hepatology, 2014, 60(3):1044–1053. https://doi.org/10.1002/hep.27137 PMID: 24666846 PMIDC: PMCID:PMC4867030

[115] Taoa C, Schreiber R, Chitraju C, Grabher GF, Romauch M, Wolinski H, Haemmerle G, Breninrauer B, Zeichner R, Laes A, Zimmermann R. Adipose triglyceride lipase is involved in the mobilization of triglyceride and retinoid stores of hepatic stellate cells. Biochim Biophys Acta, 2015, 1851(7):937–945. https://doi.org/10.1016/j.bbalip.2015.02.017 PMID: 25732851 PMIDC: PMCID:PMC4408194

[116] Okuno M, Sato T, Kitamoto T, Imari S, Kawada N, Suzuki Y, Yoshimura H, Moniwa H, Osumi K, Masushige S, Muto Y, Friedman SL, Katayama S, Tateno C, Yoshizato K. Pleiotrophin/heparin-binding growth-associated molecule as a mitogen of rat hepatocytes and its role in regeneration and development of liver. Am J Pathol, 2002, 160(6):2191–2205. https://doi.org/10.1016/S0002-9440(02)61167-4 PMID: 12057922 PMIDC: PMCID:PMC1580535

[117] Mullbaupt B, Feren A, Fodor E, Jones A. Liver expression of epidermal growth factor RNA. Rapid increases in immediate-early phase of liver regeneration. J Clin Biol Chem, 1994, 26(9): 19667–19670. PMID: 7519599

[118] Sekhon SS, Tan X, Micsenyi A, Bowen WC, Morgan SPS. Fibroblast growth factor enriches the embryonic liver cultures for hepatic progenitors. Am J Pathol, 2004, 164(6):2229–2240. https://doi.org/10.1016/j.ajpath.2004.10.037 PMID: 15161555 PMIDC: PMCID:PMC1615755

[119] Berg T, Rountree CB, Lee L, Estrada J, Sala FG, Chea A, Veltmaat JM, De Langhe S, Lee R, Tsukamoto H, Crooks GM, Bellusci S, Wang KS. Fibroblast growth factor 10 is critical for liver growth during embryogenesis and is the major hepatoblast survival via β-catenin activation. Hepatology, 2007, 46(4):1187–1197. https://doi.org/10.1002/hep.21814 PMID: 17668871 PMIDC: PMCID:PMC3494299

[120] Yin C, Evasion JJ, Asahina K, Stainier DRY. Hepatic stellate cells in liver development, regeneration, and cancer. J Clin Invest, 2013, 123(5):1902–1910. https://doi.org/10.1172/JCI66369 PMID: 23635788 PMIDC: PMCID:PMC3635734

[121] Libbrecht L, Cassiman D, Desmet V, Roskams T. The correlation between portal myofibroblasts and development of intrahepatic bile ducts and arterial branches in human liver. Liver, 2002, 22(3):252–258. https://doi.org/10.1046/j.1016-9543.2002.01674.x PMID: 12100576

[122] Sawitza I, Kordes C, Reister S, Häussinger D. The niche of stellate cells within rat liver. Hepatology, 2009, 50(5):1617–1624. https://doi.org/10.1002/hep.23164 PMID: 19725107

[123] Zong Y, Panikkar A, Xu J, Antoniou A, Raynaud P, Lemaigre F, Stainier DY. Hepatic stellate cells within rat liver. J Biol Chem, 2006, 281(26): 2899–3007. https://doi.org/10.1074/jbc.M510052200 PMID: 16877836

[124] Matsumoto K, Miki R, Nakayama M, Tatsumi N, Yokouchi Y. Wnt9a secreted from the walls of hepatic sinuosity is essential for morphogenesis, proliferation, and glycogen accumulation of chick hepatic epithelium. Dev Biol, 2008, 319(2):234–247. https://doi.org/10.1016/j.ydbio.2008.04.021 PMID: 18513713

[125] Maher JJ. Cell-specific expression of hepatocyte growth factor in liver. Upregulation in sinusoidal endothelial cells after carbon tetrachloride. J Clin Invest, 1993, 91(5):2244–2252. https://doi.org/10.1172/JCI16451 PMID: 7683700 PMIDC: PMCID:PMC2882272

[126] Zong Y, Panikkar A, Xu J, Antoniou A, Raynaud P, Lemaigre F, Stainier DY. Hepatic stellate cells – from past till present: morphology, human markers, human cell lines, behavior in normal... 633
Beng T, DeLaHenge S, Al Alam D, Utley S, Estrada J, Wang KS. β-Catenin regulates mesenchymal progenitor cell differentiation during hepatogenesis. J Surg Res, 2010, 164(2):276–285. https://doi.org/10.1016/j.sur.2009.10.033 PMID: 20381814 PMCID: PMC2904620

Hentsch B, B. Jans I, R. Hartley L, Lints TJ, Adams JM, Harvey RP. Hlx home box gene is essential for an inductive tissue interaction that drives expansion of embryonic liver and gut. Genes Dev, 1996, 10(1):70–79. https://doi.org/10.1101/gad.10.1.70 PMID: 8557196

Kubota H, Yao HL, Reid LM. Identification and characterization of vitamin A-storing cells in fetal liver: implications for functional importance of hepatic stellate cells in liver development and hematopoiesis. Stem Cells, 2007, 25(9): 2339–2349. https://doi.org/10.1634/stemcells.2006-0316 PMID: 17558172

Kordes C, Sawitza I, Müller-Marbach A, Ale-Agha N, Keitel V, Roskams T. Relationships among stellate cell activation, Curado S, Stainier DYR. deLiver’in regeneration: injury during hepatogenesis. J Surg Res, 2010, 164(2):276–285. https://doi.org/10.1016/j.jss.2009.10.033 PMID: 20381814

Ochoa B, Syn WK, Delgado I, Karaca GF, Jung Y, Wang J, Zubiaga AM, Fresneda O, Omenetti A, Zdanowicz M, Choi SS, Diehl AM. Hedgehog signaling is critical for normal liver regeneration after partial hepatectomy in mice. Hepatology, 2010, 51(5):1712–1723. https://doi.org/10.1002/hep.23525 PMID: 20422255 PMCID: PMC2920129

Schuppian D, Schmid M, Somasundaram R, Ackermann R, Ruehl M, Nakamura T, Riecken EO. Collagens in the liver extracellular matrix bind hepatic growth factor. Gastroenterology, 1998, 114(1):139–152. https://doi.org/10.1016/s0016-5085(98)70642-0 PMID: 9428228

Pi L, Ding X, Jorgensen M, Pan JJ, Oh SH, Pintille D, Brown A, Song WY, Petersen BE. Connective tissue growth factor with a novel fibronectin binding site promotes cell adhesion and migration during rat oval cell activation. Hepatology, 2008, 47(3):996–1004. https://doi.org/10.1002/hep.22079 PMID: 18167060 PMCID: PMC2196213

Taub R. Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol, 2004, 5(10):836–847. https://doi.org/10.1038/nrm1489 PMID: 15459664

Karkampouna S, Ten Dijke P, Dooley S, Julio MK. TGFβ signaling in liver regeneration. Curr Pharm Des, 2012, 18(27): 4103–4113. https://doi.org/10.2174/138111212804305212 PMID: 22630085

Ebrahimkhani MR, Oakley F, Murphy LB, Mann J, Mole A, Perugorria MJ, Ellis E, Lakey AF, Burt AD, Douglass A, Wright MC, White SA, Jaffre F, Manteaux L, Mann DA. Stimulating healthy tissue regeneration by targeting the 5-HT5B receptor in chronic liver disease. Nat Med, 2011, 17(12):1668–1733. https://doi.org/10.1038/nm.2490 PMID: 22120177 PMCID: PMC3428919

Curado S, Anderson RM, Jungblut B, Mumm J, Schroeter E, Stainier DYR. Conditional targeted cell ablation in zebrafish: a new tool for regeneration studies. Dev Dyn, 2007, 236(4): 1025–1035. https://doi.org/10.1002/dvdy.21100 PMID: 17395831

Curado S, Ober EA, Walsh S, Cortes-Hernandez P, Verkade H, Koehler CM, Stainier DY. The mitochondrial import gene tom22 is specifically required for hepatocyte survival and provides a liver regeneration model. Dis Model Mech, 2010, 3(7–8):111–115. https://doi.org/10.1242/dmm.033631 PMID: 21267827

Yin C, Evason KJ, Maher JJ, Stainier DYR. The basic helix-loop-helix transcription factor, heart and neural crest derivatives expressed transcript 2, marks hepatic stellate cells in zebrafish: analysis of stellate cell entry into the developing liver. Hepatology, 2012, 56(5):1958–1970. https://doi.org/10.1002/hep.25757 PMID: 22488653 PMCID: PMC3407311

Maher JJ. Interactions between hepatic stellate cells and the immune system. Semin Liver Dis, 2001, 21(3):417–426. https://doi.org/10.1055/s-2001-17555 PMID: 11586469

Dranoff JA, Ogawa M, Kruglov EA, Gaça MD, Sévigny J, Mahon JJ. Interactions between hepatic stellate cells and macrophages in zebrafish: analysis of stellate cell entry into the developing liver. Hepatology, 2012, 56(5):1958–1970. https://doi.org/10.1002/hep.25757 PMID: 22488653 PMCID: PMC3407311
Hepatic stellate cells – from past till present: morphology, human markers, human cell lines, behavior in normal…

[171] Bonacchi A, Petrai I, Defranco RM, Lazzeri E, Annunziato F, Eftens E, Cosmi L, Romagnani P, Milani S, Failli P, Batignani G, Liotta F, Laffi G, Pinzani M, Gentilini P, Marra F. The chemokine CCL21 modulates lymphocyte recruitment and chemotaxis in chronic hepatitis C. Gastroenterology, 2003, 125(4):1060–1076. https://doi.org/10.1016/s0016-5085(03)01194-6 PMID: 14517790

[172] Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwaabe RF. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat Med, 2003, 13(11):1324–1332. https://doi.org/10.1038/nm1663 PMID: 17452090

[173] Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology, 2014, 147(3):577–594. https://doi.org/10.1053/j.gastro.2014.04.043 PMID: 25066692

[174] Kavarnos GJ, Krüger HW, Fabbro C, Gassler N, Wasmuth HE, Luedde T, Trautwein C, Tacke F. The fractalkine receptor CX3CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology, 2010, 52(5):1769–1782. https://doi.org/10.1002/hep.24352 PMID: 21038415

[175] Safadi R, Ohta M, Alvarez CE, Fiel MI, Bansal M, Mehal WZ, Ichikawa S, Mucida D, Tyznik AJ, Kronenberg M, Cheroutre H. Casini A, Pellegrini G, Ceni E, Salzano R, Parola M, Robino G, Schildberg FA, Wojtalla A, Siegmund SV, Endl E, Diehl L, Parola M, Robino G, Bordone R, Leonarduzzi G, Casini A, March S, Graupera M, Rosa Sarrias M, Lozano F, Yamauchi M, Potter JJ, Mezey E. Characteristics of alcohol from hepatocytes. Gastroenterology, 2004, 127(3):870–882. https://doi.org/10.1053/j.gastro.2004.09.015 PMID: 15280422

[176] Lee SJ, Friedman SL, Whalen R, Boyer TD. Cellular sources of glutathione S-transferase P in primary cultured rat hepatocytes: localization by in situ hybridization. Biochem J, 1994, 299(Pt 1):79–83. https://doi.org/10.1042/bj990079 PMID: 81666622 PMID: PMC1138023

[177] DeLeve LD. Glutathione defense in non-parenchymal cells. Semin Liver Dis, 1998, 18(3):403–414. https://doi.org/10.1055/s-2000-27173 PMID: 9785557

[178] Mahler JJ, Neuschwander-Tetri BA. Manipulation of glutathione stores in rat hepatic stellate cells does not alter collagen synthesis. Hepatology, 1997, 26(3):618–623. https://doi.org/10.1053/hep.97265677 PMID: 9217726

[179] Lalazar A, Wong L, Yamasicsi G, Friedman SL. Early genes induced in hepatic stellate cells during wound healing. Gene, 1997, 195(2):235–243. https://doi.org/10.1016/s0378-1119(97)00159-5 PMID: 9305769

[180] Di Bieseier P, Heschl M, Irmisch K, Rogiers V, Geerts A. Glutathione levels discriminate between oxidative stress and transforming growth-factor-beta signaling in activated rat hepatic stellate cells. J Biol Chem, 1999, 274(48):33881–33887. https://doi.org/10.1074/jbc.274.48.33881 PMID: 10657749

[181] Kim KY, Rhim T, Choi I, Kim SS. N-acetylcysteine induces cell cycle arrest in hepatic stellate cells through its reducing effect. Biochem Biophys Res Commun, 1991, 267(4):40591–40598. https://doi.org/10.1016/j.bbrc.2007.50921 PMID: 11509553

[182] Di Sario A, Baroni GS, Battaglia E, D'Ambrosio L, Ridolfi F, Manlio JR, Gezechve AM, Benedetti A. Characterization of ion transport mechanisms regulating intracellular pH in rat hepatic stellate cells. Am J Physiol, 1997, 273(1 Pt 1):G39–G48. https://doi.org/10.1152/ajpregu.1997.273.1.G39 PMID: 9252507

[183] Cavagnati-Baroni G, Di Sario A, Cadosi A, Ferretti G, D'Ambrosio L, Ridolfi F, Bolognini L, Salzano R, Orlandi F, Benedetti A. The Na+/H+ exchanger modulates the fibrogenic effect of oxidative stress in rat hepatic stellate cells. J Hepatol, 1999, 30(5):868–875. https://doi.org/10.1016/s0168-8278(99)00044-x PMID: 10365814

[184] Paik YH, Kim J, Aoyama T, De Minicis S, Battaler R, Brenner DA. Role of NADPH oxidases in liver fibrosis. Antioxid Redox Signal, 2014, 20(17):2854–2872. https://doi.org/10.1089/ars.2013.5619 PMID: 2404957 PMID: PMC4026397

[185] Damach T, Togashi H, Suzuki A, Kasai S, Ito J, Sugahara K, Kawata S. NAD(P)H oxidase plays a crucial role in PDGF-induced proliferation of hepatic stellate cells. Hepatology, 2005, 41(6):1272–1281. https://doi.org/10.1002/hep.204352 PMID: 15915457

[186] Carvalho R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, Qian T, Schoonhoven R, Hagedorn CH, Lemasters JJ, Brenner DA. Characterization of ion transport mechanisms regulating intracellular pH in rat hepatic stellate cells. Am J Physiol, 1997, 273(1 Pt 1):G39–G48. https://doi.org/10.1152/ajpregu.1997.273.1.G39 PMID: 9252507

[187] Slevin LR, Di Sario A, Cadosi A, Ferretti G, D'Ambrosio L, Ridolfi F, Bolognini L, Salzano R, Orlandi F, Benedetti A. The Na+/H+ exchanger modulates the fibrogenic effect of oxidative stress in rat hepatic stellate cells. J Hepatol, 1999, 30(5):868–875. https://doi.org/10.1016/s0168-8278(99)00044-x PMID: 10365814

[188] Paik YH, Kim J, Aoyama T, De Minicis S, Battaler R, Brenner DA. Role of NADPH oxidases in liver fibrosis. Antioxid Redox Signal, 2014, 20(17):2854–2872. https://doi.org/10.1089/ars.2013.5619 PMID: 2404957 PMID: PMC4026397

[189] Adachi T, Togashi H, Suzuki A, Kasai S, Ito J, Sugahara K, Kawata S. NAD(P)H oxidase plays a crucial role in PDGF-induced proliferation of hepatic stellate cells. Hepatology, 2005, 41(6):1272–1281. https://doi.org/10.1002/hep.204352 PMID: 15915457

[190] Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, Qian T, Schoonhoven R, Hagedorn CH, Lemasters JJ, Brenner DA. Characterization of ion transport mechanisms regulating intracellular pH in rat hepatic stellate cells. Am J Physiol, 1997, 273(1 Pt 1):G39–G48. https://doi.org/10.1152/ajpregu.1997.273.1.G39 PMID: 9252507

[191] Slevin LR, Di Sario A, Cadosi A, Ferretti G, D'Ambrosio L, Ridolfi F, Bolognini L, Salzano R, Orlandi F, Benedetti A. The Na+/H+ exchanger modulates the fibrogenic effect of oxidative stress in rat hepatic stellate cells. J Hepatol, 1999, 30(5):868–875. https://doi.org/10.1016/s0168-8278(99)00044-x PMID: 10365814
is controlled by growth state. J Cell Biol, 1988, 107(3):1207–1213. https://doi.org/10.1083/jcb.107.3.1207 PMID: 2458361

PMC1215305

[203] Ferré N, Martínez-Clemente M, López-Parras M, González-Peña R, Planas-Navarro A, Casas J, Alonso S, Tres A, Guardiola F, Beltrán R, Arroyo V, Clárià J. Increased susceptibility to exacerbated liver injury in hypercholes-
terolemic Apo-E-deficient mice: potential involvement of oxysterols. Am J Physiol Gastrointest Liver Physiol, 2009, 296(3):G553–G562. https://doi.org/10.1152/ajpgi.00547.2007 PMID: 19136384

[204] Ramadori G, Knittel T, Schwögl F, Bieber F, Rieder H, Meyer zum Büschenfelde KH. Dexamethasone modulates alpha 2-macroglobulin and apolipoprotein E gene expression in cultured rat liver fat-storing (Ito) cells. Hepatology, 1991, 14(5):875–882. https://doi.org/10.1002/hep.1840140520 PMID: 1718836

[205] Athani A, Hänecke K, Jungermann K. Prostaglandin F2 alpha and D2 release from primary Ito cell cultures after stimulation with noradrenaline and ATP but not adenosine. Hepatology, 1994, 20(1):142–148. https://doi.org/10.1001/0022-0166-8279.0992.00127-0165 PMID: 8020883

[206] Flisiak R, Baraona E, Li J, Lieber CS. Effects of ethanol on prostanoid production by liver fat-storing cells. Hepatology, 1993, 18(5):153–159. PMID: 8325606

[207] Beno DW, Mullen J, Davis BH. Lipoxigenase inhibitors block alpha 2-macroglobulin and apolipoprotein E gene expression in cultured rat liver fat-storing (Ito) cells. Hepatology, 1991, 14(5):875–882. https://doi.org/10.1002/hep.1840140520 PMID: 1718836

[208] Bachem MG, Meyer D, Melchor R, Sell KM, Gressner AM. Activation of rat liver perisinusoidal lipocytes by transforming growth factors derived from myofibroblastlike cells. A potential mechanism of self perpetuation in liver fibrogenesis. J Clin Invest, 1992, 89(1):19–27. https://doi.org/10.1172/JCI115561 PMID: 1729271 PMCID: PMC442814

[209] Meyer DH, Bachem MG, Gressner AM. Modulation of hepatic lipoylate proteoglycan synthesis and proliferation by Kupffer cell-derived transforming growth factors type beta 1 and type alpha. Biochem Biophys Res Commun, 1990, 173(3):1122–1129. https://doi.org/10.1016/0006-291X(90)90801-S PMID: 1699522

[210] Schimchacher P, Geerts A, Jung W, Pietrangelo A, Rogler CE, Schirmacher P, Geerts A, Jung W, Pietrangelo A, Rogler CE, Meyer zum Büschenfelde KH. Dexamethasone modulates alpha 2-macroglobulin and apolipoprotein E gene expression in cultured rat liver fat-storing (Ito) cells. Hepatology, 1991, 14(5):875–882. https://doi.org/10.1002/hep.1840140520 PMID: 1718836

[211] Zindy F, Lamas E, Schmidt S, Kirn A, Brechot C. Expression of neural cell adhesion molecule (N-CAM) in adult liver. Hepatology, 1996, 24(3):670–676. https://doi.org/10.1002/hep.510240333 PMID: 8781341
Hepatic stellate cells – from past till present: morphology, human markers, human cell lines, behavior in normal...
cells in liver diseases. World J Gastroenterol. 2017, 23(43): 7666–7677. https://doi.org/10.3748/wjg.v23.i43.7666 PMID: PMC5703927

[27] Fattovich G, Struffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004, 127(5 Suppl 1):S35–S50. https://doi.org/10.1053/j.gastro.2004.09.014 PMID: 15580101

[28] Wang BB, Cheng JY, Gao HH, Zhang Y, Chen ZN, Bian H. Hepatic stem cell in inflammation–fibrosis–carcinoma axis. Anat Rec (Hoboken). 2010, 293(6):1492–1496. https://doi.org/10.1002/ar.21173 PMID: 20652399

[29] Kostallari E, Shah VH. Angiocrine signaling in the hepatic sinusoids in health and disease. Am J Physiol Gastrointest Liver Physiol, 2016, 312(2):G246–G251. https://doi.org/10.1152/ajpgi.011816.2016 PMID: 27288423 PMC: 5007289

[30] Dou C, Liu Z, Tu K, Zhang H, Chen C, Yaqoob U, Wang Y, Wen J, van Deurs J, Sicard D, Tschumperlin D, Zou H, Huang WC, Urrutia R, Shah VH, Kang N. P300 acetyltransferase mediates stiffness-induced activation of hepatic stem cells into tumor-promoting myofibroblasts. Gastroenterology, 2018, 154(8):2209–2221.e14. https://doi.org/10.1053/j.gastro.2018.02.015 PMID: 29457493 PMC: 6039101

[31] Bilzer M, Roggel F. Gerbes AL. Role of Kupffer cells in host defense and liver disease. Liver Int, 2006, 26(10):1175–1186. https://doi.org/10.1111/j.1478-3231.2006.01342.x PMID: 17105582

[32] Canbay A, Higuchi H, Bronk SF, Taniai M, Sebo TJ, Gores GJ. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest, 2003, 83(5):655–663. https://doi.org/10.1039/10.1002/hep.29803 PMID: 12360492

[33] Canbay A, Taimr P, Tokor N, Higuchi H, Friedman S, Gores GJ. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest, 2003, 83(5):655–663. https://doi.org/10.1039/10.1002/hep.29803 PMID: 12360492

[34] Lan T, Li C, Yang G, Sun Y, Zhuang L, Ou Y, Li H, Wang G, Kisseleva T, Brenner D, Guo J. Sphingosine kinase 1 promotes liver fibrosis by preventing miR-19b-3p-mediated inhibition of CCR2. Hepatology, 2018, 68(3):1070–1086. https://doi.org/10.1002/10.1002/hep.29885 PMID: 29572892 PMCID: PMC6765925

[35] Marra F, Romanelli RG, Giannini C, Faili P, Pastacaldi S, Arrighi MC, Pinzani M, Laff G, Montalto P, Gentilini P. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology, 1999, 29(1):140–148. https://doi.org/10.1002/10.1002/hep.1111/hepr.12730 PMID: 20338920 PMC: PM3695393

[36] Shearer AM, Rana R, Austin K, Baleja JD, Nguyen N, Bohm A, Covic L, Kulkoski P. Targeting liver fibrosis with a cell- penetrating protease-activated receptor-2 (PAR2) pepducin. J Biol Chem, 2016, 291(44):23188–23198. https://doi.org/10.1074/jbc.M116.732743 PMID: 27613872 PMC: 4735939

[37] Vallet SD, Ricard-Blum S. Lysyl oxidases: from enzyme activity to extracellular matrix cross-links. Essays Biochem, 2019, 63(3):349–364. https://doi.org/10.1042/EBC20180050 PMID: 31488699

[38] Perepelyuk M, Terajima M, Wang AY, Georges PC, Janmey PA, Yamauchi M, Wells RG. Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagenases and lysyl oxidases in normal liver and early after injury. Am J Physiol Gastrointest Liver Physiol, 2011, 304(6):G605–G614. https://doi.org/10.1152/ajpgi.00222.2012 PMID: 23328207 PMCID: PMC3602686

[39] Grenard P, Bresson-Hadni S, El Alaoui S, Chevallier M, Vilton DA, Ricard-Blum S. Transglutaminase-mediated cross-linking is involved in the stabilization of extracellular matrix in human liver fibrosis. J Hepatol, 2001, 35(3):367–375. https://doi.org/10.1016/s0168-8278(01)00135-0 PMID: 11592598

[40] Bonnans C, Chou J, Webz R. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol, 2014, 15(2):78–80. https://doi.org/10.1038/nrm3904 PMID: 25415508 PMCID: PMC4136204

[41] Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, Janssen J, Koppe C, Knolle P, Castoldi M, Tacke F, Trautwein C, Luedde T. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology, 2011, 53(1):209–218. https://doi.org/10.1002/hep.23922 PMID: 20890893

[42] Murakami Y, Kawada M. MicroRNAs in hepatic pathophysiology. Hepatol Res, 2017, 47(1):80–86. https://doi.org/10.1111/hepr.12730 PMID: 27101519
Hepatic stellate cells – from past till present: morphology, human markers, human cell lines, behavior in normal...
Rombouts K, Carloni V. The fibrotic microenvironment as a
Schrader J, Gordon-Walker TT, Aucott RL, van Deemter M,
Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C,
Yang JD, Nakamura I, Roberts LR. The tumor microen-
Singh SR, Rameshwar P, Siegel P. Targeting tumor micro-
Shimoda M, Mellody KT, Orimo A. Carcinoma-associated
Chen F, Zhuang X, Lin L, Yu P, Wang Y, Shi Y, Hu G, Sun Y.
Ananthakrishnan A, Gogineni V, Saeian K. Epidemiology of
Jaques DP, Coit DG, Casper ES, Brennan MF. Hepatic
Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN,
Ionescu AG, Streba LAM, Vere CC, Ciurea ME, Streba CT,
Ionescu AG, Streba LAM, Vere CC, Ciurea ME, Streba CT,
Ionescu AG, Streba LAM, Vere CC, Ciurea ME, Streba CT,
Ionescu AG, Streba LAM, Vere CC, Ciurea ME, Streba CT,
Ionescu AG, Streba LAM, Vere CC, Ciurea ME, Streba CT,
Ionescu AG, Streba LAM, Vere CC, Ciurea ME, Streba CT,
Ionescu AG, Streba LAM, Vere CC, Ciurea ME, Streba CT,
Ionescu AG, Streba LAM, Vere CC, Ciurea ME, Streba CT,
Ionescu AG, Streba LAM, Vere CC, Ciurea ME, Streba CT,
Ionescu AG, Streba LAM, Vere CC, Ciurea ME, Streba CT,
Ionescu AG, Streba LAM, Vere CC, Ciurea ME, Streba CT,
Ionescu AG, Streba LAM, Vere CC, Ciurea ME, Streba CT,
Ionescu AG, Streba LAM, Vere CC, Ciurea ME, Streba CT,
Ionescu AG, Streba LAM, Vere CC, Ciurea ME, Streba CT,
Ionescu AG, Streba LAM, Vere CC, Ciurea ME, Streba CT,
Ionescu AG, Streba LAM, Vere CC, Ciurea ME, Streba CT,
Ionescu AG, Streba LAM, Vere CC, Ciurea ME, Streba CT,
Ionescu AG, Streba LAM, Vere CC, Ciurea ME, Streba CT,
Ionescu AG, Streba LAM, Vere CC, Ciurea ME, Streba CT,
Ionescu AG, Streba LAM, Vere CC, Ciurea ME, Streba CT,
Ionescu AG, Streba LAM, Vere CC, Ciurea ME, Streba CT,
Ionescu AG, Streba LAM, Vere CC, Ciurea ME, Streba CT,
Matsuzaki K. Smad phosphoisoform signals in acute and chronic liver injury: similarities and differences between epithelial and mesenchymal cells. Cell Tissue Res, 2012, 347(1):225–243. https://doi.org/10.1007/s00441-011-1178-6 PMID: 22125891

Hayashida T. Integrins modulate cellular fibrogenesis at multiple levels; regulation of TGF-β signaling. Endocr Metab Immune Disord Drug Targets, 2010, 10(4):302–319. https://doi.org/10.2174/187153010786058803

Okabe H, Beppu T, Hayashi H, Horino K, Masuda T, Komori H, Ishikawa S, Watanabe M, Takamori H, Iyama K, Baba H. Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma. Ann Surg Oncol, 2009, 16(6):1648–1654. https://doi.org/10.1245/s10434-009-0926-0 PMID: 19540833

Annan T, Bataille F, Spruss T, Mühbauer M, Gäßele E, Schölerich J, Kiefer P, Bosserhoff AK, Hellerbrand C. Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci, 2009, 100(4):646–653. https://doi.org/10.1111/j.1349-7006.2009.01087.x PMID: 19175606

Zhao W, Zhang L, Yin Z, Su W, Ren G, Zhou C, You J, Fan J, Wang X. Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice. Int J Cancer, 2011, 129(11):2651–2661. https://doi.org/10.1002/ijc.25920 PMID: 21231322

Kang N, Gores GJ, Shah VH. Hepatic stellate cells: partners in crime for liver metastasis? Hepatology, 2011, 54(2):698–707. https://doi.org/10.1002/hep.24384 PMID: 21520207 PMC:PMC4150262

Mogler C, König C, Wieland M, Runge A, Besemfelder E, Amann T, Bataille F, Spruss T, Mühlbauer M, Gäbele E, Okabe H, Beppu T, Hayashi H, Horino K, Masuda T, Kubo N, Araki K, Kuwano H, Shirabe K. Cancer-associated fibroblasts in hepatocellular carcinoma. World J Gastroenterol, 2016, 22(20):6841–6850. https://doi.org/10.3748/wjg.v22.i30.6841 PMID: 27570421 PMC:PMC4974583

Effmova EA, Glänemann M, Liu L, Schumacher G, Settmacher U, Jonas S, Langrehr JM, Neuhaus P, Nüssler AK. Effects of human hepatocyte growth factor on the proliferation of human hepatocytes and hepatic carcinoma cell lines. Eur J Surg Res, 2004, 36(5):300–307. https://doi.org/10.1159/000079919 PMID: 15359093

Suzuki A, Hayashida M, Kawano H, Sugimoto K, Nakano T, Shiraki K. Hepatic growth factor promotes cell survival from Fas-mediated cell death in hepatic carcinoma cells via Akt activation and Fas-death-inducing signaling complex suppression. Hepatology, 2000, 32(4):796–802. https://doi.org/10.1053/hep.2000.71783 PMID: 11003625

Boix F, Rosa JL, Ventura F, Castells A, Bruix J, Rodés J. Bartrons C. m-cel mRNA overexpression in human hepatocellular carcinoma. Hepatology, 1994, 19(1):88–91. https://doi.org/10.1002/hep.2437349

Okano J, Shiota G, Kawasaki H. Expression of hepatocyte growth factor (HGF) and HGF receptor (c-met) proteins in liver diseases: an immunohistochemical study. Liver, 1999, 19(2):151–159. https://doi.org/10.1111/j.1478-3231.1999.tb00025.x PMID: 10220746

Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology, 1997, 25(4):862–866. https://doi.org/10.1002/hep.102050413 PMID: 9065889

Kaposi-Novak P, Lee JS, Gómez-Quiroz L, Coulouarn C, Factor VM, Thorgerisson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest, 2006, 116(2):496–508. https://doi.org/10.1172/JCI27236 PMID: 16714736

Yu G, Jing Y, Kou X, Ye F, Gao L, Fan Q, Yang Y, Zhao Q, Li R, Wu M, Wei L. Hepatic stellate cells secreted hepatocyte growth factor contributes to the chemoresistance of hepatocellular carcinoma. PLoS One, 2013, 8(10):e75314. https://doi.org/10.1371/journal.pone.0075312 PMID: 24203859 PMC:PMC3759390

Kopitz C, Greg M, Bandapalli OR, Ister D, Pennington CJ, Sartor RB, Rabadan R, Schwabe RF. Promotion of hepatocellular carcinoma by from Fas-mediated cell death in hepatocellular carcinoma. Cancer Res, 2005, 65(15):5466–5472. https://doi.org/10.1158/0008-5472.CAN-07-0232 PMID: 15926813

Castells A, Vizoso FJ. Importance of tumor/stroma interactions and extracellular matrix in hepatocellular carcinoma: more than a supporting role. Cancer Metastasis Rev, 2011, 30(5):504–516. https://doi.org/10.1007/s10585-011-9410-z PMID: 21789719

Darnaud M, Faivre J, Moniaux N. Targeting gut flora to prevent progression of hepatocellular carcinoma. J Hepatol, 2013, 58(2):385–387. https://doi.org/10.1016/j.jhep.2012.08.019 PMID: 22940407

Hepatic stellate cells – from past till present: morphology, human markers, human cell lines, behavior in normal…
Zhao W, Zhang L, Xu Y, Zhang Z, Ren G, Tang K, Kuang P, Bianchi G, Borgonovo G, Pistoia V, Raffagello L. Immuno-torimura T, Ueno T, Kin M, Harada R, Taniguchi E, Sancho-Bru P, Juez E, Moreno M, Khurdayan V, Morales-Taura K, De Minicis S, Seki E, Hatano E, Iwaisako K, Aleffi S, Petrai I, Bertolani C, Parola M, Colombatto S, cells in an orthotopic liver tumor mouse model. Lab Invest, 2013, 30(3):1175–2506. https://doi.org/10.1200/jco.2010.28.15_suppl.2506

Huang Y. T-cell apoptosis induced by intratumoral activated (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced Lowy I. Safety and antitumor activity of biweekly MDX-1106 PMID: 20516446  PMCID: PMC4834717

dynamics, and immunologic correlates. J Clin Oncol, 2010, 10.14670/HH-26.941  PMID: 21630223

Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, cells. Histol Histopathol, 2011, 26(7):941–951. https://doi.org/10.1038/j.1478-3231.2009.02161.x  PMID: 19929904

Lin N, Guo Y, Lyu Y, Li Y, Hu J, Zhang X, Sun X, Shen D, hepatic stellate cells in proliferation and metastasis of hepatocyte- cellular carcinoma. Hepatol Res, 2015, 45(3):326–336. https://doi.org/10.1111/hepr.12356  PMID: 24827154

Tortum T, Ueno T, Kin M, Harada R, Taniguchi E, Nakamura K, Sakata R, Hashimoto O, Sakamoto M, Kumashiro R, Sata M, Nakashima O, Yano H, Kojio M. Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J Hepatol, 2004, 40(5):799–807. https://doi.org/10.1016/j.jhep.2004.01.027  PMID: 15084226

Qu H, Yang X. Metformin inhibits angiogenesis induced by interaction of hepatocellular carcinoma with hepatic stellate cells. Cell Biochem Biophys, 2015, 71(2):931–936. https://doi.org/10.1007/s12013-014-0287-8  PM526336

Bianchi G, Bronovo G, Pietrantuono D. Immunomodulatory- suppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells. Histol Histopathol, 2011, 26(7):941–951. https://doi.org/10.14670/HH-26.941  PMID: 21630223

Chuayrisi C, Thuwalliap J, Paupairp A, Chau-In S, Suthiph- ongcchi T, Thuwalliap C. Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. Oncol Rep, 2014, 21(8):2684–2698. https://doi.org/10.1245/s10434-014-3531-y  PMID: 24682719

Schuppian D, Ashqaf-Khan M, Yang AT, Kim YO. Liver fibrosis: direct anti-biotic agents and targeted therapies. Matrix Biol, 2018, 68–69:435–451. https://doi.org/10.1016/j.matrixbio.2018.04.006  PMID: 29656147

Friedman S, Sanyal A, Goodman Z, Lefebvre E, Gottwald M, Fischer L, Raitzou V. Induction and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. Contemp Clin Trials, 2016, 47:356–365. https://doi.org/10.1016/j.cct.2016.02.012  PMID: 26944023

Narra K, Mullins SR, Lee HO, Strzemkowski-Brun B, Magalon K, Christiansen VJ, McKee PA, Egleston B, Cohen SJ, Weiner LM, Merialo NJ, Cheng JD. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer. Cancer Biol Ther, 2009, 8(11):1691–1699. https://doi.org/10.4161/cbt.6.11.8474  PMID: 19830850

Kelly T. Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist Update, 2005, 8(1–2):51–58. https://doi.org/10.1016/j.drup.2005.03.002  PMID: 15939342

Ingham PW, Nakano Y, Seger C. Mechanisms and functions of Hedgehog signalling across the metazoa. Nat Rev Genet, 2011, 12(6):393–406. https://doi.org/10.1038/nrg2984  PMID: 21502959

Corresponding author
Carmen Stanca Melincovic, Lecturer, MD, PhD, Discipline of Histology, Department of Morphological Sciences, Iuliu Hațegianu University of Medicine and Pharmacy, 4–6 Louis Pasteur Street, 400349 Cluj-Napoca, Romania; Phone +40740–219 735, e-mail: cmelincovic@yahoo.com

Received: October 23, 2020 Accepted: March 26, 2021